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INTRODUCTION: THE NEED TO ENHANCE THE
DEVELOPMENT AND EVALUATION OF HIGH VALUE DRUGS
The current rate of growth of health care costs in the United States is
unsustainable. Annual health care costs in the United States far exceed
annual health care costs in all other countries despite not providing com-
paratively high value to patients based on important health metrics such as
in-hospital case-fatality mortality (the ratio of death occurring in patients
presenting to a hospital with certain conditions, such as acute myocardial
infarction) and health care quality (in 2010, the United States ranked se-
cond lowest on health care effectiveness and patient-centeredness out of
seven industrialized countries).' Health care currently accounts for about
eighteen percent of Gross Domestic Product ("GDP"), costing approxi-
1. Uwe E. Reinhart et al., U.S. Health Care Spending In An International Context, 23 HEALTH AFF. 10-25
(2004). See also David A. Squires, The US Health System In Perspective: A Comparison of Twelve Indus-
trialized Nations, ISSUES IN INTERNATIONAL HEALTH POLICY (July 2011), available at
http://www.commonwealthfund.org/-/media/Files/Publications/Issue%20Briefl201 1/Jul/
1532_Squires US hit syscomparison 12_nationsintl brief v2.pdf (In 2008, the U.S. spent $7,538 per
capita, greater than twice the Organization for Economic Cooperation and Development ("OECD") coun-
tries' (industrialized countries) median of $2,995 and almost double as a percentage of GDP (the U.S. ver-
sus the OECD countries' median value). The U.S. also had the greatest amount of prescription drug spend-
ing and utilization per person (emphasizing the importance of evaluating drugs for their value)).
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mately $2.7 trillion, and will likely increase in future years. 2 In fact, fed-
eral health spending alone may surpass twelve percent of GDP by 2050.'
Congress recently failed to avoid the fiscal cliff, the draconian budget se-
quester, which will non-strategically decrease the funding of federal agen-
cies across the board. Thus, Congress must soon complete the seemingly
Herculean task of working together to comprehensively address the rising
national deficit and debt.4 Specifically, as the Medicare and Medicaid
health care program costs will continue to rise rapidly in the upcoming
years, members of Congress are seeking ways to decrease health care
costs, including the cost of drugs, while improving health care quality and
patient health outcomes. Despite these staggering numbers, in 2005, the
United States only spent six cents of every health care dollar on biomedi-
cal research and only one-tenth of a cent of every dollar on the long term
evaluation of which drugs work best at the lower cost (identification of
high value drugs).'
Furthermore, there is a need for a continuously learning health care
system because health care is increasing in complexity and uncertainty in
light of the many new drugs, diagnostics, and other medical interventions
that are approved every year.' Specifically, this system would enable the
generation and rapid use of evidence on health care interventions, includ-
ing drugs; in such a system, "research influences practice and practice in-
fluences research."' Additionally, the increased knowledge about the hu-
man genome has spurred the growing field of pharmacogenomics - the
2. Centers for Medicare & Medicaid Services, National Health Expenditures Projections 2011-2021,
CMS.GOv (last visited March 29, 2013), at
http://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/
NationalHealthExpendData/Downloads/Proj2011PDF.pdf. See generally, Sean P. Keehan, et al., National
Health Spending Projections Through 2020: Economic Recovery And Reform Drive Faster Spending
Growth, 30 HEALTH AFF. 1594 (2011).
3. Peter Orzag, How Health Care Can Save or Sink America, 90 FOREIGN AFF. 42 (2011).
4. WILLIAM A. MCEACHERN, MACROECONOMICS: A CONTEMPORARY INTRODUCTION, 103, 105-6 (1997)
(The annual national budget deficit is the amount by which federal expenditures in a given year exceed fed-
eral revenues. National debt is the accumulation of national deficits over time).
5. Hamilton Moses et al., Financial Anatomy of Biomedical Research, 294 JAMA 1333 (2005). See also,
Hamilton Moses & E. Ray Dorsey, Biomedical Research in the Age of Austerity, 308 JAMA 2341 (2012)
(The sequester, will significantly decrease funding for science and health agencies. For example, the NIH
budget will decrease by about eight percent and the CDC and National Science Foundation will lose hun-
dreds of millions in funding).
6. INSTITUTE OF MEDICINE, BEST CARE AT LOWER COST: THE PATH TO CONTINUOUSLY LEARNING
HEALTH CARE IN AMERICA, S-5, 2-11 (2012).
7. Sarah M. Greene, Robert J. Reid, & Eric B. Larson, Implementing the Learning Health System: From
Concept to Action, 157 ANN. INTERN. MED. 207, 208 (2012). See also MAUREEN BISOGNANO & CHARLES
KENNEY, PURSUING THE TRIPLE AIM: SEVEN INNOVATORS SHOW THE WAY TO BETTER CARE, BETTER
HEALTH, AND LOWER COSTS (2012) (This system pertains to the first part of the health reform triple aim,
the provision of better (safer, more effective, and patient-centered) health care (the other two reform aims
include better population health and lower per capita health care costs)).
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study of how genetic differences impact drug effects - with important im-
plications for personalized medicine and the development and prediction
of real world drug safety and effectiveness.! It is very difficult for pre-
scribers to keep up with all of the new drugs, interventions, and emerging
pharmacogenomic and biomedical information. Also, often clinical guide-
lines that apply to specific patients are not readily available; in fact, some
studies estimate that only ten to twenty percent of clinical decisions are ev-
idence-based.' As new interventions are contributing to the complexity of
care, so is the aging population. The first baby boomers entered the ranks
of the elderly in 2011, and by 2020, approximately 157 million people will
have at least one chronic condition.o This will add further complexity to
health care treatment regimens because elderly patients often suffer from
multiple chronic conditions and hence take several medications, which "
probably are the single most important health care technology in prevent-
ing illness, disability, and death"" in this population. Often, evidence on
the real world effectiveness of the many newly approved drugs each year
in these chronically ill populations is lacking. Furthermore, with respect to
drug safety, medication errors, an important subset of medical errors, are
more likely to occur in patients taking multiple medications (who are not
typically studied in clinical trials) and will likely increase as the elderly
population increases. Also, recent Centers for Disease Control and Pre-
vention ("CDC") evaluation of the National Electronic Injury Surveillance
8. Institute of Medicine Report, supra note 6, at S-5, 2-11; FRANCIS S. COLLINS, THE LANGUAGE OF LIFE:
DNA AND THE REVOLUTION IN PERSONALIZED MEDICINE, 238-43 (2010); Department of Health & Human
Services: Secretary's Advisory Committee on Genetics, Health and Society, Realizing the Potential of
Pharmacogenomics: Opportunities and Challenges 1 (May 2008), available at
http://oba.od.nih.gov/oba/sacghs/reports/sacghspgx report.pdf(Pharmacogenomics has significantly con-
tributed to the evaluation of which drugs work in which patients and which patients may be at risk for seri-
ous adverse reactions based on genetic mutations such as single nucleotide polymorphisms (SNPs)). See
Talitha 1. Verhoef, et al., Cost-effectiveness of pharmacogenetics in anticoagulation: international differ-
ences in healthcare systems and costs, 13 PHARMACOGENOMICS 1405, 1412 (2012). FDA has made several
drug label changes based on pharmacogenomic information and drug safety and effectiveness, e.g., Warfa-
rin, an anti-thrombotic drug commonly used to prevent serious cardiovascular events such as stroke, and
therapeutic dosing based on the activity of certain metabolic enzymes; Abacavir, a HIV drug, and serious
hypersensitivity reactions based on the "presence of genetic variants on chromosome 6"; and clopidogrel,
an anti-platelet drug used to prevent serious CV events, effectiveness based on the activity of metabolic
enzyme need to active this pro-drug). Although these label changes are important, ongoing trials are need-
ed to evaluate the cost-effectiveness of these genetic tests in light of their costs and impact on patient out-
comes.
9. Institute of Medicine Report, supra note 6, at 3-3. In addition, although clinical practice guidelines have
increased significantly in recent years, the scientific evidence undergirding these guidelines has been quite
variable and underutilized by physicians due to lack of awareness. Ronen Avraham, Clinical Practice
Guidelines: The Warped Incentives in the US Healthcare System, 37 AM.J.L. & MED. 7, 16-18 (2011).
10. PAUL J. FELDSTEIN, HEALTH POLICY ISSUES: AN ECONOMIC PERSPECTIVE 20 (2011). See also Institute
of Medicine Report, supra note 6, at S-5.
11. Jerry Avom, Medication Use in the Elderly: Current Status and Opportunities, 14 HEALTH AFF. 276
(1995).
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System ("NEISS") recently found that commonly used drugs such as an-
tithrombotics (e.g., warfarin) are responsible for a significant number of
adverse drug events in elderly patients.12 Thus, considerations of medica-
tion errors and drug safety in the elderly are important in the context of the
evaluation of the value of drugs (i.e., comparative effectiveness and safety)
in this growing population.
Despite the fact that drugs account for only about ten percent of
health care costs, the cost of prescription drugs in the United States has in-
creased significantly in recent years, and increased from $40 billion in
1990 to $250 billion in 2009.13 Furthermore, although the global market
for drugs is increasing between three percent and six percent annually,
most of this occurs not in the United States but rather in developing coun-
tries.14 Pharmaceutical companies are faced with increasing challenges as
many blockbuster drugs are now coming off patent, resulting in major
losses in profit. For example, Lipitor, a HMG coenzyme reductase inhibi-
tor (a "statin" drug, which lowers cholesterol levels) drug indicated for the
treatment of hyperlipidemia, which netted Pfizer almost $12 billion per
year, recently went off patent.' Thus, while the cost of health care and
drugs is increasing at an unsustainable rate, pharmaceutical companies are
facing great challenges in maintaining profits in the United States and will
lose over $100 billion in profits as a result of generic market entrants that
will compete with branded blockbusters. 6
Also, the efficiency of pharmaceutical company funded research has
significantly decreased, spawning the new term "Eroom's law,"" which is
the opposite of Moore's law, a prediction by Intel founder Gordon Moore
of the doubling of the "number of components that could be packed on a
[micro] chip . .. doubling of. . . memory capacity and processing speed, a
halving of size and cost" which has held true in recent decades.'" Eroom's
law describes a phenomenon that, contrary to Moore's law, describes the
halving of new drug approvals per $1 billion in Research and Develop-
ment ("R&D") approximately every nine years." Furthermore, in light of
12. Budnitz D.S. et al., Emergency Hospitalizations for Adverse Drug Events in Older Americans, 365
NEW ENG. J. MED. 2002, 2002-2012 (2011).
13. FELDSTEIN, supra note 10, at 331.
14. Pharma Sees the Start of the End, 90 CHEMICAL & ENGINEERING NEWS 28 (Feb. 27, 2012).
15. Id.
16. President's Council of Advisors on Science and Technology ("PCAST"), Report to the President on
Propelling Innovation in Drug Discovery, Development, and Evaluation, 9 (Sept. 2012).
17. Jack Scannell et al., Diagnosing the decline in pharmaceutical R&D efficiency, 11 NATURE REVS.
DRUG DISCOVERY 191 (2012).
18. JAMES GLEICK, THE INFORMATION: A HISTORY, A THEORY, A FLOOD 394 (2011).
19. Scannell, supra note 17, at 191.
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the sluggish economic recovery, funding from venture capitalists to sup-
port smaller biotechnology companies is harder to obtain.20 Despite these
challenges, it is true that the Food and Drug Administration ("FDA") ap-
provals of new molecular entities ("NMEs") were much higher than in
2011 and 2012 (twenty-four and thirty-three respectively) than in recent
years and included high value drugs, attributable in part to the increased
investment by pharmaceutical companies in specialty and orphan drugs
(see Part 1. Sect. E of this paper). 2' Thus, the industry has responded to the
"Eroom" dilemma by shifting their focus to high cost specialty and orphan
drugs that address unmet medical needs in relatively small patient popula-
tions compared to investing in drugs designed to treat the most prevalent
chronic conditions in the United States.22 It remains to be seen if this trend
to develop high cost, narrowly focused drugs will continue into the future.
Considering the impending budget sequestration, increasing national
debt (and associated decreases in funds available for federal expenditures,
including health care entitlements such as Medicare and Medicaid), and
rising cost of healthcare (e.g., medical technologies, services, drugs); in-
creasing health care complexity; and pharmaceutical and biotechnology
company monetary challenges; it is imperative to evaluate recent (from
2007-2012) federal legislative and policy initiatives to enhance the devel-
opment and evaluation of high value drugs. For purposes of this paper,
high value drugs23 ("HVDs") are defined as drugs that (1) provide good
benefit for their cost; (2) are comparatively/incrementally more effective
and/or safe relative to the standard of care, thus addressing unmet medical
needs (as stated by FDA, a "medical need not addressed adequately by an
existing therapy"24 ); and (3) improve health outcomes and metrics im-
portant to patients. Part I will discuss recent federal legislative and policy
initiatives (with some brief mention of pharmaceutical company and payer
efforts) to maximize the development and approval (premarket stage) of
high value drugs. Part II will review recent federal legislative and policy
initiatives pertaining to the evaluation (postmarket stage) of high value
therapeutics for patients. Part III will discuss potential future federal legis-
20. Id.
21. Asher Mullard. 2012 FDA Drug Approvals, 12 NATURE REVS. DRUG DISCOVERY 88 (2012).
22. Janet Woodcock, THE FUTURE OF ORPHAN DRUG DEVELOPMENT, 92 CLINICAL PHARMACOLOGY &
THERAPEUTICS 146, 146 (2012). See also Formulary Staff, New nonprofit represents specialty pharmacy,
48 FORMULARY 39, 39 (2013).
23. Institute of Medicine Report, supra note 6, at 8-5 (The Institute of Medicine points out that better met-
rics are needed to evaluate value with existing data and defines value as "the level of benefit achieved at a
given cost").
24. FDA, Guidance for Industry: Fast Track Drug Development Programs - Designation, Development,
andApplication Review 6 (Jan. 2006).
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lative and policy efforts that may further enhance the development of
HVDs and evaluation and use of these drugs. This paper does not primari-
ly focus on: efforts to improve the value of drugs by improving product
quality (e.g., anti-counterfeiting efforts, good manufacturing practice
("GMP") drug quality-related efforts to minimize substandard and falsified
drugs2 5) and decreasing health care fraud (knowingly or recklessly misrep-
resenting material facts for pecuniary gain), which accounts for significant
drug-related costs in the health care system and results in the use of drugs
that may not be valuable for patients (e.g., illegal off-label promotion of
drugs that are not effective in treating conditions for which they purported-
ly work)26; efforts to increase use of generic small molecule drugs, alt-
hough these efforts have significantly increased access to cost-effective,
valuable therapies"; health care delivery system innovations, which may
systematically enhance the impact of high value drugs by improving the
underlying infrastructure (e.g., the use of electronic health records to eval-
uate use of high value drugs in the real world)28 , global payments to re-
ward achievement of good clinical outcomes) and efforts to enhance the
communication, translation, and dissemination of evaluations of drug val-
ue, although this is also critical so patients and healthcare providers can
make informed, evidence-based decisions.29
PART I: RECENT FEDERAL LEGISLATIVE AND POLICY
INITIATIVES TO MAXIMIZE THE DEVELOPMENT
25. See generally GILLIAN J. BUCKLEY & LAWRENCE 0. GoSTIN, INSTITUTE OF MEDICINE (1M),
COUNTERING THE PROBLEM OF FALSIFIED AND SUBSTANDARD DRUGS (2013) and Janet Woodcock & Mar-
ta Wosinska, Economic And Technological Drivers of Generic Sterile Injectable Drug Shortages, 93
CLINICAL PHARMACOLOGY & THERAPEUTICS 170, 171-2 (2013) (These references provide an in depth dis-
cussion of the policy challenges associated with drug product quality issues,).
26. TERRY L. LEAP, PHANTOM BILLING, FAKE PRESCRIPTIONS, AND THE HIGH COST OF MEDICINE:
HEALTH CARE FRAUD AND WHAT TO Do ABOUT IT 3 (2011) (In 2009, fraudulent Medicare and Medicaid
payments alone were approximately $54 billion).
27. Generic competition under the Hatch-Waxman Act of 1984 has served as the primary "driver of declin-
ing prices for several highly prescribed drug classes." As many of these drugs are HVDs, this has signifi-
cantly increased patient access to HVDs by making these drugs affordable. See Henry Grabowski et al.,
Evolving Brand-Name and Generic Drug Competition May Warrant a Revision of the Hatch-Waxman Act,
11 HEALTH AFF. 2157, 2163 (2011).
28. See American College of Cardiology Annual Scientific Session & Expo 2012: Formulary decision pro-
cess at Mayo Clinic leads to abandoning 80-mg dose of simvastatin, 47 FORMULARY 340 (2012) (Recently
the Mayo Clinic used electronic health records ("EHRs") to evaluate the use of simvastatin 80 mg, after a
FDA drug safety communication discussed the increased risk associated with muscle damage at this dose.
As many patients were taking this high risk dose of the drug (based on a review of EHRs), the clinic's task-
force leveraged this knowledge to communicate with physicians and patients about this safety issue and
inform their clinical decision-making about the appropriate therapy).
29. See generally Bethany Fox, Closing the Information Gap: Informing Better Medical Decisionmaking
Through the Use of Post-Market Safety and Comparative Effectiveness Information, 67 FOOD & DRUG L.J.
83 (2012).
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(PREMARKET STAGE) OF HIGH VALUE DRUGS
A. Background
There are important, recent legislative and policy initiatives under-
taken by the federal government to maximize the development of high
value drugs ("HVDs"). This section will evaluate these initiatives and
their potential impact on the development of HVDs. In the context of drug
development enhancements, the recent report by the President's Council of
Advisors on Science and Technology ("PCAST") pointed out specific
challenges including the high failure rate of drugs throughout the approval
process, regulatory uncertainty, high expenses, long time to market,
amongst other challenges.30 To support the United States' economic com-
petitiveness and innovation, in addition to enhancing public health out-
comes, PCAST set an ambitious goal to "double the annual output of new
medicines for patients with important unmet medical needs, while increas-
ing drug efficacy and safety through industry, academia and government
working together."' Jack Scannell and colleagues point out the following
policy challenges in drug development that may impede PCAST's ambi-
tious goal: (1) as more drugs have been approved, it is more difficult to ob-
tain approval and reimbursement for high value drugs (e.g., producers of a
new drug for acid reflex must attempt to provide added value to the current
H2 blockers and proton pump inhibitors ("PPIs") if they wish their drugs
to be reimbursed)3 2; (2) the low hanging fruit problem of development of
drugs with easily identified targets (which may not provide additional val-
ue compared to currently available drugs); (3) the cautious regulator prob-
lem; and (4) the "throw money at it" tendency, which involves the com-
mitment of significant resources without understanding factors that affect
return on investment." These policy challenges must be addressed to im-
prove drug development in the United States; the initiatives discussed be-
low will address some of these challenges.
B. The FDA Safety and Innovation Act: Legislative Initiatives
In July 2012, President Obama signed into law the omnibus FDA bill,
the FDA Safety and Innovation Act (FDASIA), which includes new user
fee authorizations and re-authorizations for prescription drugs (PDUFA),
30. PCAST, supra note 16, at 13-15.
31. PCAST, supra note 16.
32. Scannell, et al., supra note 17, at 194.
33. Id.
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medical devices (MDUFA), generic drugs (GDUFA), and biosimilars
("BSUFA") and will enable FDA to collect up to $6 billion in the next five
years. 34 This law, which is organized into eleven titles, includes several
provisions designed to stimulate the development of high value drugs. Ti-
tles III and IV provide for user fees to speed up the approval of small mol-
ecule generic drugs (Title III) and biosimilars (Title IV). After the advent
of the Drug Price Competition and Patent Restoration Act (Hatch-Waxman
Act) of 1984, the development and approval of generic drugs has signifi-
cantly decreased the price of high value drugs once brand drugs go off pa-
tent, historically resulting in savings of $8 billion to $10 billion annually
which has increased in recent years to just under $200 billion per year."
However, in recent years, FDA has accumulated a significant backlog of
generic drug applications due to understaffing. The funds from the Gener-
ic Drug User Fee Act and provisions will increase staffing and support ef-
forts to expedite the review of generic drugs, enhance the post-market
safety evaluation of such drugs, and ensure product quality." Funding for
this authorization was tenuous in light of the recent continuing resolution
passage to fund the federal government with the same level of funding as
the prior fiscal year; but, at the last minute Congress passed a bill that ena-
bled FDA to begin collecting user fees on October 1, 2012, and thus FDA
can move forward with this new user fee program. The program will sig-
nificantly reduce review times from thirty months to ten months." This
provision of FDASIA will expedite the approval of generic drugs, enabling
earlier access to drugs that improve health outcomes at a much lower cost.
However, as a significant percent of the market use already uses generic
drugs once they are available, this will have a modest, albeit important, ef-
fect on the approval and use of such drugs by speeding access to them by
just under two years.
Congress recently authorized a new abbreviated approval pathway for
34. Food and Drug Administration Safety and Innovation Act ("FDASIA"), Pub. L. No. 112-144 (2012).
Jill Wechsler, FDA user fee legislation speeds drug approvals, address shortages, counterfeits, 47
FORMULARY 306 (2012).
35. See Congressional Budget Office, How Increased Competition from Generic Drugs Has Affected Pric-
es and Returns in the Pharmaceutical Industry (Jul. 1998). These savings are now much greater in light of
the patent expiration of several blockbuster drugs in recent years (e.g., Lipitor). See also The Generic
Pharmaceutical Association, Savings: $1 Trillion Over 10 Years; Generic Drug Savings in the US. (2012),
available at www.gphaonline.org/media//cms/IMSStudyAug20l2WEB.pdf (last visited Mar. 06, 2013).
36. FDASIA, Pub. L. No. 112-144 (2012) at Title 1II; Margaret A. Hamburg, Remarks at the Annual Con-
ference of the Food and Drug Law Institute, FOOD & DRUG L.J. 123, 126 (2012).
37. FDA User Fee Corrections Act of 2012, H.R. 6433 (approved by the House and Senate July 2012).
38. Government Accountability Office, Savings from Generic Drug Use, GAO-12-371R at 2 (Jan. 31,
2012) (seventy-eight percent of drugs that are dispensed in retail pharmacies are generics, and this percent-
age may increase in upcoming years in light of the expiration of blockbuster drug patents).
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biosimilar drugs, defined as "highly similar" to their reference biologic
products, in the Patient Protection and Affordable Care Act ("ACA")." In
2012, FDA published guidance documents on the approval of biosimi-
lars. 40  Title IV of FDASIA provides for biosimilar drug user fees. This
provision can significant expedite and enhance the approval of affordable
high value biologic therapies in the future. This is important as many of
these biologic drugs are extremely expensive; for example, Cerezyme, a
drug used to treat Gaucher disease, costs approximately $200,000 per
year.4 1 In addition in 2012 biologic drugs accounted for a majority of clin-
ic and hospital drug expenditures.42  Thus, the expedited approval of bio-
similars could stimulate the development and approval of beneficial bio-
logic drugs at a lower cost, increasing the value of these drugs.
Importantly, more pharmaceutical and biotechnology companies are
seeking to develop these therapies because they provide high value and are
much more profitable than small molecule drugs, which are subject to
more competition (i.e., generics). However, the development of biologic
drugs, which are much more complex (i.e., protein folding) than small
molecule drugs, 43 is much more expensive and involves a complex manu-
facturing process. Thus, due to these high barriers to entry, the market for
biosimilars is anticipated to be much smaller than that of small molecule
generic drugs. The market for biosimilars may increase in future years
with advancements in analytical technology and it is estimated that it will
be approximately $2 billion to $2.5 billion annually by 2015 (the Congres-
sional Budget Office scored approximately $7 billion in savings over a
ten-year timeframe from the use of biosimilars.) 44 Thus, biosimilars will
39. Patient Protection & Affordable Care Act ("PPACA"), Pub. L. No. 111-148 (2010), Title VII, §§ 7001-
7003, Biologics Price Competition and Innovation ("BPCI") Act of 2010.
40. See FDA, Guidance for Industry on Biosimilars: Questions & Answers Regarding Implementation of
the BPCIAct of 2009 (Feb. 2012).
41. Geeta Anand, How Drugs for Rare Diseases Became the Lifeline for Companies, WALL ST. J., Novem-
ber 15, 2005, available at http://online.wsj.com/article/SBl13202332063297223.html. Robert Pear, Con-
gress Seeks Compromise on Generic Drugs, N.Y. TIMES, April 8, 2007, available at
http://www.nytimes.com/2007/04/08/washington/08drug.html.
42. James Hoffman et al., Projecting Future Drug Expenditures, 63 AM. J. HEALTH SYS. PHARM. 298, 531,
533 (2013).
43. Janet Woodcock et al., The FDA s assessment offollow-on protein products: a historical perspective, 6
NAT. REVS. DRUG DISCOVERY 437, 438 (2007).
44. IMS Health, Shaping the biosimilars opportunity: a global perspective on the evolving biosimilars
landscape 1 (Dec. 2011). This is relatively small compared to the global biopharmaceutical market, esti-
mated to be $856 billion in 2010) and spending on prescription drugs in the U.S., which was approximately
$250 billion in 2009 (see CMS, Office of the Actuary, National Health Statistics Group (2011) available
at: http://www.cms.gov/NationalHealthExpendData/downloads/tables.pdf; JOHN E. MCDONOUGH, INSIDE
NATIONAL HEALTH REFORM 230 (2011)). In addition, the "complex patent litigation procedures" for bio-
similars may limit the utility of the market exclusivity associated with interchangeable biosimilar products.
See Kenneth J. Szetzo & Marian Wolanski, Initial Steps in the Regulation of Generic Biological Drugs: A
512
2013] FEDERAL HIGH VALUE DRUGS INITIATIVES
likely enhance approval of cost-effective valuable drugs in the longer term
but in the near term will likely not have the same impact on prices and
value as small molecule generics. Furthermore, unique comparative safety
issues associated with complex biologic drugs (in contrast to small mole-
cule drugs), such as immunogenicity,4 5 may make clinicians less likely to
prescribe biosimilars in the future, even if required clinical studies are
completed; for example, a small manufacturing process change in the pro-
duction of the biologic Eprex (a red blood cell production stimulator) re-
sulted in patients experience a severe, immunogenicity-related condition,
pure red cell aplasia.46
In addition to the above user fee programs, FDASIA includes provi-
sions to stimulate the development of drugs that address unmet medical
needs. The law enhances patient access under accelerated approval and
creates a "breakthrough therapy" designation for drugs.47 During the in-
ception of the expedited development and accelerated approval programs
in the 1980s, the focus was on important unmet medical needs such as
HIV/AIDS and cancer.48 The accelerated approval program facilitates in-
creased communication between FDA and drug sponsors early on to "seek
agreement on the design of necessary preclinical and clinical studies need-
ed to gain marketing approval."49 This communication expedites the rapid
development and review of these products that address unmet medical
needs."o
In 1997 Congress codified this program as the "Fast Track" program
in the FDA Modernization Act ("FDAMA")." In the 2006 FDA guidance
on the fast track program, FDA defined "unmet medical need" with re-
spect to serious conditions as follows: (1) no available therapy; (2) availa-
ble therapies but: (i) superior effect on serious outcomes, (ii) effect on se-
rious outcomes not affected by other therapies, (iii) ability to provide
benefit while avoiding serious toxicity, or (iv) ability to provide benefit for
Comparison of US. and Canadian Regimes, 67 FOOD & DRUG L.J. 131, 137 (2012).
45. Meenu Wadhwa & Robin Thorpe, Unwanted Immunogenicity: Implications for Follow-On Biologicals,
412 DRUG INFO. ASS'N 1 (2007). See also Hans C. Ebbers et al., Interchangeability, immunogenicity and
biosimilars, 30 NATURE BIOTECHNOLOGY 1186, 1187 (2012).
46. Charles Bennett et al., Pure Red-Cell Aplasia and Epoetin Therapy, 351 NEW ENG. J. MED. 1403-1408
(2004).
47. FDASIA, Pub. L. I12-144 (2012), at Title IX, §§ 901 & 902.
48. 53 Fed. Reg. 41516 (October 21, 1988). See also PETER BARTON HUTT ET AL., FOOD & DRUG LAW
650 (3d ed. 2007).
49. Id
50. Scannell, supra note 17, at 2. See also FDA, Guidance for Industry: Fast Track Drug Development
Programs - Designation, Development, and Application Review 2 (Jan. 2006) [hereinafter FDA Guidance:
Fast Track Drug Development Programs].
51. FDA Modernization Act ("FDAMA"), Pub. L. 105-115 (2007), Sec.112.
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patients who can't tolerate alternative therapies; and (3) the only available
therapy was approved under accelerated approval.52 It is important to bear
this unmet medical need definition in mind when evaluating the new
FDASIA provisions pertaining to accelerated approval. One critical aspect
of this program has been the early and informative feedback from FDA to
the drug sponsors and strong collaborations between the two." Also, the
accelerated approval process has enabled FDA to approve drugs for these
serious conditions to address unmet medical needs based on "surrogate"
outcomes (e.g., clinical laboratory values); this is essential as it enables
approval of drugs without long clinical trials, although it underscores the
need to evaluate health outcomes in the post-market setting (i.e., Phase IV
studies) to ensure the drugs are safe and effective. Overall, drugs ap-
proved under the expedited development program have been made availa-
ble significantly faster than drugs not approved under the program and the
"total regulatory phase" was 3.3 years less during the period between 1988
and 1993 for drugs in the program compared to drugs not approved under
the program.54 In addition, the "five original drugs" approved under the
accelerated approval program were approved more quickly, including a
FDA review phase with a mean of 8.3 months." Thus, the program has
successfully accelerated the development and approval of high value
drugs.
In Section 901 of FDASIA, the law stipulates that after the initial es-
tablishment of the accelerated access program, advancements in science,
such as genomics and molecular biology, along with innovative clinical
trial designs and other aspects of drug development, have enabled the crea-
tion of targeted, novel, and innovative therapies.5 6 In light of these devel-
opments, the law describes Congress' interest in ensuring that the FDA
take steps to increase access to these innovative drugs, thus addressing
unmet medical needs for serious or life threatening diseases or conditions.
Society's focus on enhancing patient access to drugs that address unmet
medical needs is illustrated, by the recent efforts of the FDA before
FDASIA enactment to enhance access to HVDs. For example, in 2009,
the FDA enhanced previous expanded access efforts by promulgating a fi-
52. FDA Guidance: Fast Track Drug Development Programs, supra note 50, at 6.
53. HUTT, supra note 48, at 648-49. See also Sheila Shulman & Jeffrey Brown, The Food and Drug Ad-
ministration's Early Access and Fast Track Approval Initiatives: How Have They Worked?, 50 FOOD &
DRUG L.J. 503, 512 (1995).
54. Id. at 513.
55. Id at 516.
56. FDASIA, supra note 47, at § 901. The law will also enable FDA to use more flexibility when evaluat-
ing endpoints for drugs under accelerated approval. See, Cheryl Thompson, Rare-disease drugs to receive
consideration on par with serious-disease drugs, 69 AM. J. HEALTH SYs. PHARM. 1936, 1937 (2012).
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nal rule on expanded access to investigational drugs for individual patients
and intermediate size patient populations." This increased access to
HVDs for a small, but important group of patients with unmet medical
needs. This afforded access to approximately 3,000 patients, thus increas-
ing overall access to patients with serious or life-threatening conditions to
approximately 56,000 patients."
Section 901 of FDASIA requires the FDA to consider the application
of the accelerated approval program to a "broad range" of serious or life-
threatening conditions and the FDA has indicated its intention to expand
accelerated approval in light of this section of the law. In addition, the
FDA will develop a guidance on surrogate endpoints which will inform
industry of FDA's latest thinking on this issue and help companies to un-
derstand when they can pursue this approach. 60 This increased certainty
may increase industry's investment in the HVDs that may be approved via
this streamlined "surrogate" based approach. In Section 902, Congress
created a "breakthrough therapy" designation. 6 ' This section is designed to
decrease the time of development of HVDs. Drugs are designated as
breakthrough therapies if they are to be used for treatment of a serious or
life-threatening condition and "preliminary clinical evidence indicates that
the drug may demonstrate substantial improvement over existing therapies
on one or more clinically significant endpoints, such as substantial treat-
ment effects observed early in clinical development." 62 Thus, the new
provision focuses on enhancing the development of drugs with a compara-
tively high value, when compared to currently available drugs with the
same indication. The law authorizes the FDA to take specific actions to
expedite the development of breakthrough drugs, including: (1) holding
meetings with the sponsor throughout drug development; (2) providing
advice on the necessary clinical and non-clinical data for the development
program; (3) involving senior managers; (4) establishing a cross-
disciplinary review team leader; and (5) taking steps to ensure the clinical
trial process is efficient." The FDA will now "issue initial instructions to
industry about how it will identify a breakthrough drug"' and is required
to publish a draft guidance on implementation of the breakthrough therapy
57. Expanded Access to Investigational Drugs for Treatment Use, 74 Fed. Reg. 40901 (2009).
58. Id. at 40930.
59. FDASIA, supra note 47 at § 901; Brett Norman, The Food and Drug Administration Gets New Tools
to Spur Regulatory Science. 31 HEALTH AFF. 1919, 1919-1922 (2012).
60. Id at 1921.
61. FDASIA, supra note 47, at § 902, Breakthrough Therapies.
62. Id.
63. Id.
64. Norman, supra note 59, at 1920.
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provisions. 65  Although the impact of these provisions remain to be seen,
the national disease specific organizations, who represent patients, have
significant expertise on the rare diseases that might be addressed by break-
through therapies. They will provide important stakeholder input on this
approach, staunchly support this provision, and think it will enhance the
development and approval of important HVDs.66 However, it is possible
that the FDA may have worked with sponsors to accelerate these therapies
on their own initiative and now the agency may instead be bogged down in
reviews required of drugs meeting the criteria instead of collaborating di-
rectly with sponsors via the current process." The FDA's required guid-
ance on the breakthrough therapy provision, which must be completed by
2014, may alleviate this problem by informing the industry of how this
provision may be applied by the FDA."
In addition, FDASIA includes a provision to extend the patent exclu-
sivity period for new qualified infectious disease products to stimulate the
development of much needed new antibiotics." The lack of antibiotics is a
significant unmet medical need. Most of the 2 million hospital-acquired
infections that occur annually are caused by pathogens resistant to bacte-
ria, causing significant morbidity and mortality and costing over $30 bil-
lion each year.70 It is similar to the Hatch-Waxman Act of 1984, which pa-
tients with serious diseases supported, because it incentivized
pharmaceutical companies to develop drugs to treat conditions for which
there was not any available therapeutic by extending patent terms." It is
also similar to FDAMA and the Best Pharmaceuticals for Children Act
("BPCA"), which provided for additional market exclusivity in exchange
for the conduct and completion of studies to provide evidence on the safe-
ty and effectiveness of drugs in children, patients are counting on the cur-
rent market exclusivity provisions to enhance the development of access to
65. FDASIA, supra note 47, at § 902.
66. Norman, supra note 59, at 1919. See also, Wechsler, supra note 34.
67. Michael McCaughan, Breakthrough Therapy: New Pathway in FDASIA May Point the Way for Future
Reforms, 8 THE RPM REPORT 8 (2012).
68. FDASIA, supra note 47, at § 902.
69. FDASIA, supra note 47, at §. 505E. [355fj, Extension of patent exclusivity for new qualified infectious
disease products.
70. Infectious Disease Society of America, Antibiotic Resistance (Oct. 12, 2012), available at
http://www.idsociety.org/uploadedFiles/IDSA/Policy_and _Advocacy/Current Topics and Issues/
Antimicrobial Resistance/WHD/Antibiotic%20Resistance%20Fact%2OSheet(1).pdf (Bacterial sepsis and
pneumonia killed over 50,000 patients in the U.S. in 2006 and resulted in $8 billion in health care costs).
71. Drug Price Competition and Patent Restoration ("Hatch-Waxman") Act, Pub. L. 98-417 (1984). See
also DOMINQUE TOBBELL, PILLS, POWER, AND POLICY: THE STRUGGLE FOR DRUG REFORM IN COLD WAR
AMERICA AND ITS CONSEOUENCES 204 (2012).
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high value therapies.72 As BPCA continues to significantly increase the
development of drugs to treat children, this provision may also enhance
the development of high value antibiotics by addressing the market failure
attributable to the low profitability of these drugs."
Section 908 of FDASIA contains provisions for a priority review
voucher program to stimulate investment in the development of therapies
for the treatment of rare pediatric diseases, an important unmet medical
need.74 This program is modeled on the priority review voucher program
from the FDA Amendments Act ("FDAAA") of 2007, which was created
to stimulate investment in tropical neglected diseases." Upon a drug
sponsor's successful development of a drug indicated to treat a rare pediat-
ric disease, the law provides for FDA to grant priority review of another
drug product (e.g., a product that the sponsor anticipate will be highly
profitable, such as one to treat a highly prevalent, chronic disease). Alt-
hough in theory this voucher is valuable because it could enable a sponsor
to get a highly profitable drug on the market faster, providing for earlier
profit accrual, the priority review voucher program has not been very suc-
cessful and has only resulted in the approval of one drug to treat a neglect-
ed disease. 76  One reason this may not have attracted much industry inter-
est is because it requires investment in costly clinical trials for these rare
diseases, which are risky in light of the high cost and failure rates of tri-
als. In addition, the recent Canadian experience with priority approvals
indicates that drugs approved under an accelerated paradigm may be asso-
72. FDA Modernization Act ("FDAMA"), Pub. L. 105-115 (1997); see Best Pharmaceuticals for Children
Act, Pub. L. 107-109 (2002).
73. Rib-X Pharmaceuticals, Rib-X Pharmaceuticals Receives Qualified Infectious Disease Product (QIDP)
Designation from the FDA for Delafloxacin, (Sept. 17, 2012), available at
http://www.reuters.com/article/2012/09/17/idUS82683+17-Sep-2012+BW20120917 (FDA designated
delafloxacin, develop by Rib-X Pharmaceuticals as one of the first QIDPs soon after the passage of
FDASIA). See also FDA, CDER, & HHS, Public Hearing, Establishing a List of Qualifying Pathogens
That Have the Potential to Pose a Serious Threat to Public Health (Dec. 18, 2012), transcript available at
http://www.fda.gov/downloads/Drugs/NewsEvents/UCM338748.pdf (During this meeting, drug sponsors,
including the company Rib-X, whose product received the first QIDP designation, emphasized the im-
portance of the extended market exclusivity in stimulating investment in this area, especially for small
companies with limited resources and no or few successful products on the market).
74. FDASIA, supra note 47, at § 908; Industry Gains Incentives for Drugs for Children. 2 CANCER
DISCOVERY 758 (2012).
75. FDA Amendments Act of 2007, Pub. L. 110-85, Sect. 1102.
76. Brenda Sandburg, FDA Awards First-Ever Priority Review Voucher to Novartis for Coartem Approval,
THE PINK SHEET 005 (Apr. 8, 2009); Tatum Anderson. Novartis under fire for accepting new reward for
old drug, 373 LANCET 1414 (2009). See also, Michael McCaughan, The End of the Priority Review
Voucher (Revisited), THE RPM REPORT (2012) (indicating that Novartis is still the first and only company
to receive a priority review voucher for developing a drug to treat neglected diseases (as of February
2012)).
77. Gerald F. Anderson, Spurring New Research for Neglected Diseases. 28 HEALTH AFF. 1750, 1752
(2009).
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ciated with increased safety issues."
FDASIA requires FDA to "solicit views of patients during the medi-
cal product development process" by creating a process for a patient repre-
sentative to attend drug development meetings between drug sponsors and
FDA and identifying patients with minimal conflicts of interest." This
statutory requirement will enhance patient input in the drug development
process and in turn increase the focus drug development discussions on pa-
tient, in addition to regulatory and prescriber-based consideration. Fur-
ther, in the PDUFA V goals letter, which lists the PDUFA funding reau-
thorization commitments, FDA also highlights important regulatory
science and policy-related initiatives by FDA that will enhance the devel-
opment of HVDs.so With respect to patient-reported outcomes ("PROs"),
the FDA will hire new staff with relevant clinical and statistical expertise,
provide consultations on and promote best practices for the development
of PROs, and integrate the new staff into new drug divisions."' This will,
in turn, improve HVD development by providing for a "greater under-
standing of challenges that arise during development of outcomes assess-
ment tools, potential strategies to overcome these challenges, and greater
consistency in FDA's approach to the review, qualification, and usage of
these tools as part of the drug development process."82 The PRO provi-
sions are especially important in light of the developing evidence base
supporting the positive effect of shared decision-making (with patients and
healthcare professionals) on the improvement of patient health outcomes
in a complex medical care environment." Obtaining patient input and fo-
cusing on outcomes important to patients when developing medical inter-
ventions, including drugs, may lead to the approval of drugs which signifi-
cantly improve patient quality of life and other important patient-focused
measures and hence provide significant value. The Institute of Medicine
("IOM") recently asserted, "a learning health care system is anchored on
patient needs and perspectives."84 FDA's PRO-related efforts will be con-
sistent with this approach and support the development of HVDs in such a
78. Joel Lexchin, New Drugs and Safety: What Happened to New Active Substances Approved in Canada
Between 1995 and 2010? 172 ARCH. INTERN. MED. 1680, 1680-1681 (2012).
79. FDASIA, supra note 47, at § 1137.
80. See FDA, PDUFA Reauthorization Performance Goals and Procedures: Fiscal Years 2013 Through
2017 (2011), at http://www.fda.gov/downloads/Forlndustry/UserFees/PrescriptionDrugUserFee/
UCM270412.pdf.
81. Id. at 21.
82. Id at 22.
83. Annette O'Connor et al., Toward the Tipping Point: Decision Aids and Informed Patient Choice, 26
HEALTH AFF. 716, 716-725 (2007).
84. Institute of Medicine Report, supra note 6, at 5-5.
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system. Furthermore, the clinical trial-related PRO methods development
can enhance the rapid testing and approval of HVDs. In addition, under
PDUFA V, FDA will be advancing the development of biomarkers. This
is critical to the development of high value drugs for certain conditions
such as cancer, which is a disease of genetic progression. Targeted drugs
have been developed based on biomarkers that can predict drug effective-
ness and safety in the real world, such as effects on molecular targets and
inductions of certain enzymes that may increase drug toxicity."
C. The Patient Protection and Affordable Care Act (ACA):
Legislative Initiatives
There are some key legislative initiatives in the ACA, in addition to
the biosimilars pathway mentioned above, that may enhance the develop-
ment and approval of high value drugs. One key legislative initiative in
ACA is the Cures Acceleration Network ("CAN"), which was created to
support translational research" that may accelerate the development of
high value drugs and other medical products." Specifically, this may ad-
dress the fact that "95% of drugs fail in [increasingly expensive] clinical
trials, with 82% [of the drugs] dying in Phase II alone."" This low rate of
success has stymied the development of cures, and as a result, in recent
years less HVDs have been developed to address unmet medical needs and
cure diseases.8 9 The genesis of this provision stems from Senator Joseph
Lieberman's proposal during the Democratic presidential primary to sup-
port the development of cures by funding a $150 billion federal initiative
to support the development of disease cures." In 2005, Senator Lieberman
introduced the American Center for Cures Act91 which emphasized the im-
portance of funding translational research,9 2 especially in light of the in-
85. Gary Kelloff & Caroline Sigman, Cancer Biomarkers: selecting the right drug for the right patient, 11
NATURE REVS. DRUG DISCOVERY 201, 203 (2012).
86. Patient Protection and Affordable Care Act of 2010, Pub .L. 111-148, Sec. 10409, Cures Acceleration
Network.
87. Id.
88. STEVE OLSON & ANNE B. CLAIBORNE, INSTITUTE OF MEDICINE, ACCELERATING THE DEVELOPMENT
OF NEW DRUGS AND DIAGNOSTICS: MAXIMIZING THE IMPACT OF THE CURES ACCELERATION NETWORK 6
(2012).
89. Sharon Begley & Mary Carmichael, Desparately Seeking Cures, NEWSWEEK, May 14, 2010, available
at http://www.newsweek.com/id/238078.
90. OLSON & CLAIBORNE, supra note 88, at 3.
91. American Center for Cures Act of 2005 [hereinafter "Cures Act"], S.2104 (109th Congress).
92. Id. (Senator Lieberman defined translational research as "investigation in which knowledge obtained
from fundamental research such as with genes, cells, or animals, is transformed through early and late state
development prototyping and testing into diagnostic or therapeutic interventions that can be applied to the
treatment or prevention of disease or frailty.")
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creasing complexity of chronic diseases, which at the time accounted for
billions of dollars spent in the United States on health care each year (this
amount will increase due to the aging population). Specifically, the bill
would have created an American Center for Cures within the National In-
stitute of Health ("NIH") whose mission would be to "increase the capaci-
ty of the National Institute of Health to promote translational research" to
"speed the development of effective therapies, diagnostics, and cures es-
sential to human health and well being."93 This Center would have imple-
mented a strategy for translational research, including prioritization and
funding of innovative multi-disciplinary projects guided by "Grand Chal-
lenges" to direct the research community in undertaking projects that
"transform the healthcare environment," such as nanotechnology, stem cell
research, infrastructure to facilitate studying the human genome, develop-
ment of rapid vaccine manufacturing capacity, a fast track clinical trial in-
frastructure, antibiotic resistance, and other projects.94 Also, the Center
would have facilitated the development of HVDs by providing funding to
develop drugs to treat conditions without a large, continuous market, such
as antibiotics (there is an unmet need for new antibiotics in light of in-
creasing resistance to existing agents and the emergence of superbugs) and
vaccines (the current technology was based solely on egg-based produc-
tions, which limits rapid production and there is still a great need for a
HIV vaccine). The Center also was tasked with supporting infrastructure
development that individual corporations did not support on their own,
such as human genomics research infrastructure. Importantly, the bill au-
thorized $5 billion a year to "support research and development of break-
through biomedical discoveries via grants, contracts, and cooperative
agreements to public and private sector organization."96 Half of the funds
would be allocated to the Health Advanced Projects Research Agency,
modeled after the Defense Advance Research Projects Agency
("DARPA"), which has successfully funded innovative high risk projects
in the defense technology arena that are too risky for companies to pursue.
The bill would have also created a Center for Cures Council composed of
the directors of the key federal health agencies, including NIH, CDC,
FDA, the Agency for Healthcare Research & Quality ("AHRQ"), other or-
ganizations such as the Institute of Medicine, small businesses, and the bi-
93. Id.
94. Cures Act, supra note 91.
95. The flu vaccine shortage in 2004 was caused in part by our continued reliance at the time on the old
intensive egg-based vaccine production process. See TIM BROOKES, CHAPTER 3: MAKING FLU VACCINE, in
INFLUENZA AND THE 2004 FLU VACCINE SHORTAGE, 15-22 (2005).
96. Cures Act, supra note 91.
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opharmaceutical industry. These leaders with significant expertise from
these technical agencies, institutes and industry would make recommenda-
tions to the Cures Director on research priorities.
The bill also would have set up Federally Funded Research and De-
velopment Centers ("FFRDCs") to carry out Center activities in consulta-
tion with representatives from private industry, institutions of higher edu-
cation, other federal agencies, and other organizations." FFRDCs are
hybrid organizations that address needs of the United States via private
companies whose strengths lie in "their flexibility to assemble teams of
technical experts on a project basis" and they are designed to "translate re-
search into projects."" Thus, this was an important aspect of the Cures
Act as it would enable multi-disciplinary teams to successfully fund risky,
translational research to develop cures. In addition, the Cures Act also
would have created the Health Advanced Research Projects Agency
("HARPA"), modeled after DARPA. This agency would have consisted
of several portfolio managers and would be flexible, non-hierarchical, and
have substantial freedom and incentives to fund high-risk projects that
may translate research into cures. Further, the staff would rotate in and out
every three to five years, thus continuing the cycle of funding innovative
managers and researchers. These innovative entities would have the flexi-
bility and ability to fund high-risk projects that could develop HVDs (in
contrast to NIH, generally, which is subject to significant funding rules
and restrictions). Other provisions would have included support of cen-
tralized institutional review boards ("CIRBs") to expedite the review pro-
cess 9 , provisions for funding small businesses to stimulate investments in
translational research, assistance in the regulatory product development
process for small companies, database creation of translational research,
patent incentive provisions, and a Center for Excellence in Clinical Bioin-
formatics to support the development of tools and methods.'" Overall, the
comprehensive bill authorized a significant amount, $50 billion in ten
years', and supported numerous approaches to stimulate translational re-
search and ultimately, the development of cures for serious conditions. In
97. Id.
98. Kevin R. Kosar, The Quasi Government: Hybrid Organizations with Both Government and Private
Sector Legal Characteristics 11 (2011), available at http://www.fas.org/sgp/crs/misc/RL30533.pdf.
99. The Centralized IRB proposal is a critical one because one of the main challenges in conducting trials
of potentially high value drugs is the fact that multi-site studies currently require increased time and effort,
in addition to reduced protection of patients, due to the current regulations requiring cumbersome multi-site
IRB reviews for these studies. See Jerry Menikoff, The Paradoxical Problem with Multiple-IRB review,
363 NEW ENG. J. MED. 1591, 1592-3 (2010).
100. Cures Act, supra note 91.
10 1. Id.
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2008, Senator Lieberman reintroduced this bill in the 2008 Congress under
the new name, the Accelerating Cures Act.102 This bill would have also
created a FFRDC, although for clinical effectiveness research, and the
HARPA, similar to the 2005 bill, to support translational research.'03 The
bill also included the CIRB provisions to streamline research, and support
for the training of translational researchers and small businesses.'"
Senator Arlen Specter introduced a bill in 2009 to create an extra-
NIH entity that would significantly increase authorization for NIH funding
and authorize $1 billion in funds for the new Cures Acceleration Net-
work.' 5 In the Patient Protection and Affordable Care Act, with the sup-
port of Senator Arlen Specter, who was interested in Lieberman's concepts
and saving the biotech industry, Congress created the CAN within NIH.
The ACA authorized $500 million in 2010 for CAN to provide grants and
awards, including some percentage of DARPA-type funding for high risk
projects (Cures Acceleration Flexible Research Awards), building on Sen-
ator Lieberman's model. In the Consolidated Appropriations Act of 2012,
Congressed moved the CAN into the newly created National Center for
Advancing Translational Sciences ("NCATS").'" NCATS is important
because it is the first NIH Center to comprehensively focus on the "science
and technology of drug development."o' Specifically, CAN created three
grant programs, the Cures Acceleration Partnership, Cures Acceleration
Grant, and Cures Acceleration Flexible Research Programs. CAN's func-
tions are to "conduct and support revolutionary advances in basic re-
search" to translate this research into cures, "award grants to accelerate the
development of high need cures," "facilitate review by FDA for high need
cures funded by FDA" to make sure CAN considers FDA approval re-
quirements, and appropriate FDA technical assistance is provided.'s The
CAN is authorized to use "other transactional authority ('OTA')," which
decreases restrictions on funding that may be caused by federal regula-
tions. In particular, the OTA may alleviate restrictions caused by the
Bayh-Dole Act (which can be restrictive to companies)', and NIH re-
quirements, facilitating the funding of translational projects."' This au-
thority and the focus on collaboration and communication with industry
102. Accelerating Cures Act of 2008, S.2988 (l10th Congress).
103. Id. at 11, 20.
104. Id. at 28.
105. Cures Acceleration Network Act, S.914 (1llth Congress).
106. Consolidated Appropriations Act of 2012, Pub. L. 112-74.
107. PCAST, supra note 16, at 52.
108. OLSON & CLAIBORNE, supra note 88, at 6.
109. Id. at 35.
110. Id. at 7.
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via public-private partnerships are effective methods to stimulate transla-
tional research (e.g., newer animal models, stem cell biology techniques,
development of platform technologies to "reveal molecular signatures of
disease progression and drug responses")"' that may result in the devel-
opment of HVDs. However, the FY 2012 budget for the CAN was only
$10 million, a mere 0.2 percent of the annual funding Senator Lieberman
authorized for the Cures Center in his seminal 2005 bill, and one percent
of the funds Sen. Specter subsequently authorized in his bill. Thus, alt-
hough CAN efforts address translational research - an important aspect of
the development of HVDs - the funding is likely insufficient to signifi-
cantly address this need even though parts of the funding require matching
dollars from recipients.112 By contrast, the Biomedical Advanced Research
and Development Authority - authorized under the Pandemic and All-
Hazards Preparedness Act of 2006"3 and designed to increase the devel-
opment of medical countermeasures, including drugs, for terrorist events
(e.g., a biological attack) - has a current budget of $1.6 billion."4 The
PCAST points out that CAN will only address a small aspect of the HVD
development problem due to low appropriated funding ($10 million)."'
Also, CAN does not have the ability to leverage FFRDCs, which, as men-
tioned, provide significant flexibility in developing innovative products.
This will decrease CAN's effectiveness in contrast to prior comprehensive
legislative proposals, which authorized significantly more funding. Final-
ly, CAN does not constitute a comprehensive approach to address multiple
HVD development challenges. Senator Lieberman's broad approach,
which would mandate that one Center holistically address translational re-
search, clinical trials, genomics infrastructure, market failures with antibi-
otic and vaccine development issues, flexible approaches, and many other
translation research and drug development issues, may have accelerated
multi-disciplinary, collaborative, and focused solutions to related prob-
lems."' However, NCATS as a whole addresses some aspects of this
broader approach (albeit without the $5 billion per year funding envi-
sioned by Senator Lieberman's 2005 bill), and FDASIA provisions ad-
dress others (e.g., the extension of market exclusivity for high value anti-
111. Id. at 17.
112. See id. at 25 (CAN requires recipients of the Cures Acceleration Partnership Awards to "contribute . .
. $1 for every $3 awarded.")
113. Pandemic and All-Hazards Preparedness Act of 2006, Pub. L. 109-417, 120 Stat. 2831 (2006).
114. Pandemic and All-Hazards Preparedness Act of 2006, supra note 113; OLSON & CLAIBORNE, supra
note 88, at 37.
115. PCAST, supra note 16, at 19.
116. See id. at 51 (for example, the PCAST report points out that there is still a major unmet need to im-
prove the clinical trials enterprise, which would enhance the development of HVDs).
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biotics). In addition, FDA and NIH are collaborating on regulatory sci-
ence initiatives which include translational efforts to link NIH's basic sci-
ence-funded research with FDA's public health regulatory approval au-
thorities."7 Thus, Congress' piecemeal approach and other federal policy
initiatives may address some of the gaps Senator Lieberman's bill intended
to fill, although not nearly as comprehensively.
D. CMS-FDA Policy Initiative to Expedite Access to Novel Medical
Interventions
In 2010, the FDA announced that it was considering, along with the
Centers for Medicaid and Medicare Services ("CMS"), "a process for
overlapping evaluations of premarket, FDA-regulated medical products
when the product sponsor and both agencies agree to such parallel re-
view.""' The purpose of this voluntary, formal process would be to de-
crease the time between FDA approval and CMS national coverage deter-
minations. Doing so would potentially decrease the time it would take
high-value interventions (e.g., devices) to reach Medicare and Medicaid
patients, a group that currently numbers approximately ninety-five million
people, which will significantly increase in the future in light of the aging
population and optional expansion of Medicaid under the ACA." 9 As
such, a significant portion of the United States' population could potential-
ly have access to such high-value interventions earlier. The FDA ensures
that products are safe and efficacious in the premarket setting, and CMS
evaluates whether the medical items and services it may cover are reason-
able and necessary.'20 Although parallel review could increase access to
high value drugs by decreasing time from FDA approval to return on in-
vestment via approval by CMS, it is not currently likely to have a signifi-
cant impact on drugs because most undergo local coverage determinations
("LCDs") versus national coverage determinations (the proposed parallel
review programs would only apply to NCDs).12' After reviewing the pub-
117. Margaret A. Hamburg, Advancing Regulatory Science, 331 SCIENCE 987, 987 (2011).
118. Parallel Review of Medical Products, 75 Fed. Register, 57,045 (2010).
119. Nat'l Fed'n of Indep. Bus. v. Sebelius, 132 S. Ct. 2566 (2012) (The Supreme Court's landmark deci-
sion prohibited the federal government from withholding all federal Medicaid funding if states fail to ex-
pand Medicaid coverage to non-pregnant childless adults with an income under 133% of the federal poverty
level).
120. Federal Food, Drug, and Cosmetic Act, Pub.L. 75-717, 52 Stat. 1040 (1938) (current version at 21
U.S.C. § 301 et seq. (2009)); Kefauver Harris Amendment, Pub. L. 87-78 (1962); Social Security Act, Pub.
L. 74-271, Sec.1862(a)(1), 49 Stat. 627 (1935).
121. John Carlsen, et al., Drug and Device Approval/Clearance and FDA-CMS Parallel Review, DIA
Webinar (Feb. 16, 2011) (Ninety percent of CMS coverage decisions are local coverage determinations).
See Inside CMS, Drugs Removed From CMS' List Of Possible NCDs On Back Burner, For Now,
INSIDEHEALTHPOLICY.COM (2012), at http://insidehealthpolicy.com/201212122418787/
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lic comments, the FDA and CMS have started a voluntary pilot program
focused on medical devices as many more of these products undergo
NCDs than drugs. 122
E. Recent Pharmaceutical Companies' Focus on Specialty Drugs
Pharmaceutical companies are also focusing on HVDs by shifting
their investments into specialty drugs (e.g., TNF alpha blockers for the
treatment of rheumatoid arthritis), which are innovative and address unmet
medical needs by targeting unique causes of serious diseases such as can-
cer and multiple sclerosis.123 Annual pharmaceutical companies' revenues
from specialty drugs relative to total revenue increased from thirty-nine
percent in 2001 to forty-five percent in 2006, illustrating the increasing
market share of these drugs in recent years. 124 However, these HVDs are
very expensive - in 2008, the average spending for specialty drugs per pa-
tient was $11,746 - and access to these medications may thus be limited
even though patients have shown a willingness to pay substantial out-of-
pocket costs for these drugs when feasible.125
PART II. RECENT FEDERAL LEGISLATIVE AND POLICY
INITIATIVES PERTAINING TO THE EVALUATION
(POSTMARKET STAGE) OF HIGH VALUE DRUGS FOR
PATIENTS
A. Introduction
As mentioned earlier, there has been an increased focus on the valua-
tion of drugs in light of the budgetary crossroads in the United States.
Several recent legislative and policy initiatives seek to enhance the valua-
tion of drugs, including drug comparative effectiveness and safety and pa-
Health-Daily-News/Daily-News/drugs-removed-from-cms-list-of-possible-ncds-on-back-burner-for-
now/menu-id-212.html (Although some drugs were included on a potential NCD list in 2008, these have
been dropped in light of the lack of inclusion of drugs in the most recent NCD list generated from public
comments).
122. FDA-CMS Parallel Review (Oct. 13, 2012), at http://www.fda.gov/MedicalDevices/
DeviceRegulationandGuidance/HowtoMarketYourDevice/PremarketSubmissions/ucm255678.htm.
123. John A. Romley et al., Survey Results Show That Adults Are Willing to Pay Higher Insurance Premi-
ums for Generous Coverage of Specialty Drugs, 31 HEALTH AFF. 683-90 (2012).
124. McKinsey & Company, Invention Reinvented: McKinsey Perspectives on Pharmaceutical R&D
(20 10), at http://www.mckinsey.com/-/media/mckinsey/dotcom/client-service/
pharma%20and%20medical%20products/pdfs/rdemergingmarkets.ashx. See also Stacy Lawrence, Billion
dollar babies-biotech drugs as blockbusters, 25 NATURE BIOTECHNOLOGY 380-382 (2007) (In fact, some
estimates predict that biologic drugs will constitute four of the top five selling drugs by 2014).
125. Romley, supra note 123, at 684.
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tient-centered outcomes. To facilitate efficacy evaluation, drugs are often
studied in relatively small, healthy patient populations during the pre-
approval phases (e.g., a Phase III clinical approval trial may include a few
thousand patients), which may not produce generally reliable evidence on
real world health outcomes. For example, trials may not include patients
representative of those that will take the drug in the post-market real world
setting and may not be adequately powered (i.e., small sample size) to
evaluate drug safety, especially rare adverse events.'26 Thus, there is a
considerable amount of uncertainty regarding the effectiveness and safety
of drugs used in the real world, and it is important to evaluate how effec-
tive and safe a drug is when actually used widely in the population.'27 As
noted previously, the recent IOM report on the learning health care system
pointed out the lack of useful evidence on medical intervention-related
outcomes of importance to the decisionmakers: patients and clinicians.
Furthermore, the recently published IOM report addressing issues associ-
ated with studying the safety of approved drugs points out the considerable
controversy surrounding the appropriate risk estimate threshold for evalu-
ating the validity of observational pharmacoepidemiologic safety studies
(drug safety studies) and the ability to make causal inferences based on
these studies.'28 In the judicial world, the scientific manual for judges dis-
cusses the risk estimate threshold of 2.0 - above which one may "believe"
the findings from an observational study of an association - that may be
used in drug tort liability cases, although this is not a legally-binding
rule.129  Although further research is needed to determine risk estimate
thresholds for specific drug and safety issues pairs, one researcher has lev-
eraged the work of a NIH researcher in the 1960s and applied this to the
126. Patients in the real world may have many more chronic conditions and take multiple medications
which may impact the effectiveness and safety of a drug in the real world. For example, although almost
thirty percent of the population suffer from multiple chronic conditions, including a majority of elderly pa-
tients, in recent years, few randomized controlled trials, which are used to demonstrate drug efficacy and
safety in the premarket setting, have included patients that have multiple co-morbidities, limiting the gener-
alizability of clinical trial evidence on effectiveness and safety to the real world population. See Alejandro
Jadad et al., Consideration of Multiple Chronic Diseases in Randomized Controlled Trials, 306 JAMA
2670, 2671 (2011); Sebastian Schneeweiss, Developments in Post-marketing Comparative Effectiveness
Research, 82 CLINICAL PHARMACOLOGY & THERAPEUTICS 143 (2007); Tarek A. Hammad et al., Second-
ary Use ofRCTs to Evaluate Drug Safety, 8 CLINICAL TRIALS 559, 561 (2011).
127. Additionally, off-label use is prevalent and may increase in the future due to efforts to accelerate ap-
proval of drugs indicated for narrow populations. See, Aaron Kesselheim, Off-Label Use and Promotion:
Balancing Public Health Goals and Commercial Speech, 37 Am. J.L. & MED. 225, 227 (As there is often
limited evidence on drug safety and effectiveness for off-label uses, which may lead to increased patient
harms, it is important to evaluate these uses in the real world); Gerald Dal Pan, Monitoring the Safety of
Medicines Used Off-Label, 91 CLINICAL PHARMACOLOGY & THERAPEUTICS 787-95 (2012).
128. INSTITUTE OF MEDICINE, ETHICAL AND SCIENTIFIC ISSUES IN STUDYING THE SAFETY OF APPROVED
DRUGS (2012), available at http://books.nap.edu/openbook.phprecord-id=13219.
129. REFERENCE MANUAL ON SCIENTIFIC EVIDENCE 381-86 (3d ed. 2011).
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pharmacoepidemiology world.130 Such an approach may inform future ef-
forts in this area to address uncertainty around observational studies so
they can increase confidence in this form of evaluative evidence. Although
it is appropriate for a regulatory agency such as FDA to consider whether a
drug can work for the purpose of market approval, it is incumbent upon
payers to evaluate how a drug does work in the real world.'3 ' This enables
evaluation of its value by patients; in other words, does it work for me and
is it worth it?' 32 The Congressional Budget Office ("CBO") defined com-
parative effectiveness research ("CER") as a rigorous evaluation of the
impact of different options that are available for treating a medical condi-
tion for a particular set of patients. Such a study may compare similar
treatments like competing drugs, or it may analyze very different ap-
proaches such as a surgery and drug therapy. The analysis may focus only
on the relative medical benefits and risks of each option, or it may also
weigh both the costs and benefits of those options."' 3 Thus, according to
this definition, pharmaceutical CER involves a valuation relative to other
drugs. The Federal Coordinating Council on Comparative Effectiveness
Research defined CER as the:
conduct and synthesis of systematic research comparing different in-
terventions and strategies to prevent, diagnose, treat, and monitor health
conditions. The purpose of this research is to inform patients, providers,
decision-makers . . . about which interventions are most effective for pa-
tients under specific circumstances . . . . Defined interventions compared
may include medications, procedures, medical and assistive devices and
technologies . . . . This research necessitates the development, expansion,
and use of a variety of data sources and methods to assess comparative ef-
fectiveness research." 34
The Institute of Medicine defines CER as "the generation and synthe-
sis of evidence that compares the benefits and harms of alternative meth-
130. Sebastian Schneeweiss, Sensitivity analysis and external adjustment for unmeasured confounders in
epidemiologic database studies of therapeutics, 15 PHARMACOEPIDEMIOLOGY & DRUG SAFETY 291, 291-
303 (2006); Irwin D.J. Bross, Pertinency of an Extraneous Variable, 20 J. CHRONic DISEASES 487-95
(1967).
131. Bryan Luce, Michael Drummond, Bengt Jnsson et al., EBM, HTA, and CER: Clearing the Confu-
sion. 88 Milbank Quarterly, 256, 267 (2010), available at http://www.ncbi.nlm.nih.gov/pmc/
articles/PMC2980346/.
132. Id.
133. Congressional Budget Office, Research on the Comparative Effectiveness of Medical Treatments:
Issues and Options for an Expanded Federal Role 3 (Dec. 2007) at
http://www.cbo.gov/sites/default/files/cbofiles/ftpdocs/88xx/doc8891/12-18-comparativeeffectiveness.pdf.
134. United States Department of Health and Human Services, Draft Definition of Comparative Effective-
ness Research for the Federal Coordinating Council, HHS.GOV/RECOVERY (2009) available at
http://www.hhs.gov/recovery/programs/cer/draftdefinition.html.
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ods to prevent, diagnose, treat, and monitor a clinical condition to improve
the delivery of care. The purpose of CER is to assist consumers, clini-
cians, purchasers, and policymakers to make informed decisions that will
improve health care at the individual and population levels."' 35 This paper
will adopt a definition of drug comparative effectiveness that reflects all of
these definitions but eschews the cost aspect, because although this is an
important aspect of effectiveness research, it is not the focus of relevant,
recent federal legislative and policy initiatives: the generation and synthe-
sis of evidence comparing the effectiveness and safety of two or more
drugs in general and specific sub-populations to facilitate evidence-based
decision-making by patients, health care professionals, and other decision-
makers.
B. American Recovery and Reinvestment Act (ARRA) Funding for
Federal Comparative Effectiveness Research
Historically, there has been significant congressional interest in learn-
ing about the effectiveness and safety of medical interventions in the real
world. In 1987, Senator David Durenberger established the Patient Out-
comes Research Teams ("PORTs") to evaluate outcomes of surgical inter-
ventions on important health conditions such as angina or chest pain due to
coronary artery disease.136 This in part stimulated the development of the
Agency for Health Care Policy and Research ("AHCPR") in 1989, whose
name was changed to the Agency for Health Care Research and Quality
("AHRQ") in 1999.137 Importantly, because this outcomes research on
medical interventions, including drugs, can create "winners" and "losers,"
it has been controversial and funding for ACHPR/AHRQ has nearly been
eliminated by Congress multiple times since its inception, including re-
cently.138 In the 2003 Medicare Modernization Act, Congress established
the Effective Health Care ("EHC") Program within AHRQ to "improve
the quality, effectiveness, and efficiency" of the federal Medicare, Medi-
caid, and CHIP programs that now include a significant percentage of pa-
tients in the United States, with the number expected to grow in light of
135. INSTITUTE OF MEDICINE, INITIAL NATIONAL PRIORITIES FOR COMPARATIVE EFFECTIVENESS
RESEARCH 29 (2009).
136. JOHN E. WENNBERG, TRACKING MEDICINE: A RESEARCHER'S QUEST TO UNDERSTAND HEALTH
CARE 89 (2010).
137. Id. at 89.
138. Id. at 99. In 1994, ACHPR's report on lower back pain, which found that first line surgery for this
condition was not supported by good evidence, stimulated lower back surgeons to lobby Congress to elimi-
nate the agency. See, Mike Mitka, Critics of US House Proposal to Ax AHRQ Says Idea is Penny-wise and
Pound-foolish, 308 JAMA 849, 849-50 (2012) (Also, recently the House of Representatives recommended
eliminating AHRQ).
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the aging population and ACA-related Medicaid expansion. Under the
EHC program, AHRQ collaborates with researchers to conduct reviews
and synthesize evidence on medical interventions (via research reviews),
including drugs, generate scientific evidence and tools (via original re-
search and reports), and translate evidence for use by patients, health care
professionals, and policy makers (via research summaries/guides).13 9 In
addition, the National Institutes of Health ("NIH") has funded influential
comparative effectiveness clinical trials, including on drugs, in the past.14
In 2009, Congress appropriated $1.1 billion for comparative effectiveness
research, including $300 million allocated to the Agency for Healthcare
Research and Quality, $400 million to NIH (this was transferred from
AHRQ), and $300 million to the Office of the Secretary of Health and
Human Services ("OS/HHS").141 Approximately forty-six percent of these
funds have been allocated to evidence development and synthesis, forty-
one percent to improve the infrastructure, enhance data and methods, sev-
en percent for dissemination and translation, and five percent for prioriti-
zation and stakeholder engagement. 142 One of the key comparative effec-
tiveness research gaps is the development methodologies and
infrastructure to leverage electronic health care data (administrative claims
and electronic health record data), which include information on health
outcomes in the real world setting. In light of the significant congressional
funding supporting the adoption of electronic health records and resultant
increase in adoption in the next few years , it is critical to maximize use
of this population data for comparative effectiveness research. AHRQ
used $25 million of the ARRA CER funds to support distributed research
network ("DRN") pilot projects to leverage these data sources for the CER
evaluation of medical intervention, including drug, outcomes in the real
139. Medicare Prescription Drug Improvement and Modernization Act of 2003, P.L. 108-173, Sec. 1013.
See also What Is the Effective Health Care Program, AGENCY FOR HEALTHCARE RESEARCH & QUALITY,
at http://www.effectivehealthcare.ahrq.gov/index.cfn/what-is-the-effective-health-care-programl/
(AHRQ's DEcIDE and CERTs programs fund investigators to conduct research on the clinical comparative
effectiveness and safety of a variety of medical treatments, including drugs).
140. For example, NIH funded the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart At-
tack Trial ("ALLHAT") trial that evaluates the effectiveness and safety of different anti-hypertensive medi-
cations. The trial found that older, less expensive thiazide diuretic drugs were as effective as newer, more
costly (i.e., on patent) anti-hypertensive drugs. ALLHAT Officers and Coordinators for the ALLHAT Col-
laborative Research Group, Major outcomes in high-risk hypertensive patients randomized to angiotensin-
converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid-
Lowering Treatment to Prevent Heart Attack Trial (ALLHA T), 18 JAMA 2981-97 (2002).
141. American Recovery and Reinvestment Act of 2009, Pub. L., 111-5.
142. Joshua S. Benner et al., An Evaluation of Recent Federal Spending on Comparative Effectiveness Re-
search: Priorities, Gaps, and Next Steps, 29 HEALTH AFF. 1768, 1770 (2010).
143. American Recovery and Reinvestment Act of 2009, Pub. L., 111-5., HITECH Act. The HITECH Act
provided just under $30 billion in funding to support the adoption of interoperable electronic health records.
CMS is currently funding stage two of this effort under the auspices of meaningful use.
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world and is currently building off these distributed research network pro-
totypes.1" Importantly, the DRN approaches eschew some important pa-
tient privacy problems by enabling health data holders to keep their data
behind their own firewalls while transforming their data into a common
format to facilitate comparative effectiveness studies using e-health data
on patients across various health plans. HHS/Assistant Secretary for Plan-
ning and Evaluation ("ASPE") has also used some of the ARRA funds to
fund data infrastructure projects, for example, a multi-payer claims data-
base without patient identifiable information (to address privacy issues)
that can inform large comparative effectiveness studies of real world pa-
tient outcomes in Medicare and privately insured populations.'45 Despite
these important and ongoing data development efforts funded by ARRA,
there is a need for continued and increased funding of these projects and
related methods development to ensure the increasingly available electron-
ic health data can be used to evaluate the comparative effectiveness of
drugs (and other interventions) and patient health outcomes.
One of the key challenges of comparative effectiveness research is
that most of the relevant studies, approximately eighty-five percent, are
observational versus randomized studies.'46 Traditional evidentiary hierar-
chies, which position randomized controlled trials higher than observa-
tional studies (with respect to quality of evidence), "attempt to replace
judgment with an overly simplistic, pseudoquantitative, assessment of the
quality of available evidence" 47 and hence are not always useful in specif-
ic drug comparative effectiveness circumstances. Although observational
studies reflect real world drug effectiveness and safety, in contrast pre-
market randomized controlled trials, these studies are subject to more bias
and confounding than randomized studies which may lead to misleading
144. Benner, supra note 142, at 1771; Jeff Brown et al., Enhanced Functionality for the Distributed Re-
search Network Pilot, EFFECTIVE HEALTH CARE PROGRAM RESEARCH REPORT NUMBER 37, at
http://effectivehealthcare.ahrq.gov/ehc/products/215/1027/DEclDE37_DistribResearch finalreport 201204
03.pdf (The Distributed Research Network projects were funded initially to leverage existing intellectual
and data resources for the conduct of rapid cycle comparative effectiveness research studies. Specifically,
the projects focus on "standardized and re-usable information technology approaches for speeding the initi-
ation and conduct of large-scale comparative effectiveness studies, including studies of treatments covered
by Medicaid, Medicare, SCHIP, and other Federal payers." Users, such as payers like CMS, can then use
the comparative effectiveness evidence from such studies, in conjunction with other evidence sources, to
inform decisions about medical interventions, including drugs).
145. Andre Chappel, NCVHS Full Committee Meeting. Multi Payer Claims Database for Comparative
Effectiveness Research, NATIONAL COMMITTEE ON VITAL & HEALTH STATISTICS (Jun. 16, 2011), at
http://www.ncvhs.hhs.gov/1 10 6 16 pl.pdf; Amol Navanthe et al., Advancing Research Data Infrastructure
for Patient-Centered Outcomes Research, 306 JAMA 1254, 1255 (2011).
146. Michael L. Johnson & Abishek S. Chitnes, Comparative Effectiveness Research: guidelines for good
practices are just the beginning, 11 EXPERT REVS. 51, 53 (2011).
147. Sir Michael Rawlins, De testimonio: on the evidence for decisions about the use of therapeutic inter-
ventions, 372 LANCET 2152, 2152-2161 (2008).
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results.148 One significant form of confounding observational studies may
suffer from is "confounding by indication" which "can occur when the un-
derlying diagnosis [indication] or other clinical features that affect the use
of a certain drug are also related to the outcome under study" and may
threaten the validity of observational studies of effectiveness and safety.'49
When new drugs are approved, they may be reserved for sicker patients,
thus complicating the evaluation of the outcomes in patients on new drugs
compared to other drugs used to treat the same condition (i.e., confounding
by indication). In addition, observational pharmacoepidemiologic CER
studies which use secondary electronic health care data may suffer from
unmeasured confounding; these studies lack information on relevant con-
founders, such as smoking, body mass index ("BMI"), over-the-counter
("OTC") use of aspirin, etc., it may be difficult to discern the comparative
effectiveness of the COX-II inhibitors versus NSAIDs, as these unmeas-
ured confounders may account for the observed difference in outcomes
versus the actual drugs of interest.'" Thus, one critical aspect of CER is
the development of methods to handle bias and confounding (in the in-
stances in which confounding is not so great as to preclude the conduct of
a useful observational study). Independent organizations and agencies
have developed best practices for observational pharmacoepidemiologic
studies, including the FDA (focused on drug safety)"' and the European
Network of Centers on Pharmacoepidemology and Pharmacoepidemiolo-
gy,152 supported by the European Medicines Agency ("EMA"), FDA's Eu-
148. Michael Lauer & Francis Collins, Using Science to Improve the Nation's Health System: NIH's com-
mitment to Comparative Effectiveness Research, 303 JAMA 2182, 2183 (2010). One example that is often
cited is the Women's Health Initiative observational study, which initially found that postmenopausal hor-
mone therapy was cardioprotective before a through evaluation of the study design highlighted the healthy
user bias, that women who stayed on the drug were healthier than those who did not, biasing the results.
See, J.E. Rossouw, et al., Risks and benefits of estrogen plus progestin in healthy postmenopausal women:
principal results From the Women's Health Initiative randomized controlled trial, 288 JAMA 321, 321-33
(2002); Sean Tunis et al., Comparative effectiveness research: Policy context, methods development and
research infrastructure, 29 STAT. IN MED. 1963, 1969 (2010).
149. BRIAN STROM, PHARMACOEPIDEMIOLOGY 922 (2012). See also, Michael Barry, Helping Patients
Make Better Personal Health Decisions: The Promise of Patient-Centered Outcomes Research, 306 JAMA
1258, 1259 (2011); Bruce M. Psaty & David S. Siscovick, Minimizing Bias Due to Confounding by Indica-
tion in Comparative Effectiveness Research: The Importance ofRestriction, 304 JAMA 897, 897-8 (2010).
150. Schneeweiss, supra note 126.
151. FDA, Draft Guidance for Industry and FDA Staff Best Practices for Conducting and Reporting
Pharmacoepidemiologic Safety Studies Using Electronic Healthcare Data Sets (Feb. 2011). The FDA is
also enhancing its epidemiology program and increasing access to data sources for the evaluation of post-
market drug safety. See Judy Staffa & Gerald Dal Pan, Regulatory innovation in postmarketing risk as-
sessment and management, 91 CLINICAL PHARMACOLOGY & THERAPEUTICS 555, 555-7 (2012); Margaret
A. Hamburg, The Growing Role of Epidemiology in Drug Safety Regulation, 22 EPIDEMIOLOGY 622, 622-
624(2011).
152. ENCePP Guide on Methodological Standards in Pharmacoepidemiology, EUROPEAN NETWORK OF
CENTRES FOR PHARMACOEPIDEMIOLOGY AND PHARMACOVIGILANCE, at
http://www.encepp.eu/standards andguidances/index.shtml. ENCePP's efforts to develop best practices
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ropean counterpart, the International Society of Pharmacoepidemiology
("ISPE")'", and the Good ReseArch for Comparative Effectiveness
("GRACE") group of experts. 15 4  Recently, epidemiologists developed a
preliminary evaluative framework and reviewed potential tools that may
facilitate the consistent evaluation of observational pharmacoepidemiolog-
ic safety studies for regulatory decision-making; GRACE is developing a
checklist for the evaluation of observational pharmacoepidemiologic CER
studies for use by payers and others.' The development of "specialized"
methods for observational pharmacoepidemiologic CER research, such as
high dimensional propensity scores and instrumental variables' to handle
confounders, are critical to these observational studies so it is possible to
tease out the comparative impact of drug effectiveness and safety (i.e.,
value) in the real world and enhance confidence in this important evidence
source. Furthermore, EMA has established a process via ENCePP to reg-
ister observational studies, increasing the transparency of studies that may
be used for regulatory decision-making.'
A recent article posited that Clinicaltrials.gov could support observa-
tional pharmacoepidemiologic study registration in the United States. 15
Currently, per the Food and Drug Administration Amendments Act
("FDAAA") requirements, companies are required to register Phase II to
IV clinical trials and may register observational studies.'59 Although re-
quired registration of observational pharmacoepidemiologic studies would
and register observational pharmacoepidemiologic studies will increase transparency but will fail to guaran-
tee quality, although this is not the intent of ENCePP; Sebastian Schneeweiss & Jerry Avorn, Postmarket-
ing studies of drug safety: A European initiative could help bring more transparency and rigour to phar-
macoepidemiology, 342 BMJ 344 (2011).
153. International Society for Pharmacoepidemiology ("ISPE"), Guidelines for good pharmacoepidemiol-
ogy practices (GPP), 17 PHARMACOEPIDEMIOLOGY & DRUG SAFETY 200 (2008).
154. Good Research for Comparative Effectiveness (GRACE) Checklist, GRACE PRINCIPLES, available at
http://www.graceprinciples.org/doc/GRACE-Checklist-0 11013-v3.pdf.
155. George A. Neyarapally et al., Review of Quality Assessment Tools for the Evaluation ofPharmacoep-
idemiologic Safety Studies, BMJ OPEN (2012), available at
http://bmjopen.bmj.com/content/2/5/eOO I 362.full.pdf; GRACE Checklist supra note 154.
156. John Concato, Is It Time for Medicine Based Evidence?, 307 JAMA 1641 (2012); Sebastian Schnee-
Weiss, Methods for developing and analyzing clinically rich data for patient-centered outcomes research:
an overview, 21 PHARMACOEPIDEMIOLOGY & DRUG SAFETY 1, 3 (2012).
157. Electronic Register of Studies, EUROPEAN NETWORK OF CENTRES FOR PHARMACOEPIDEMIOLOGY
AND PHARMACOVIGILANCE, at http://www.encepp.eu/encepp/studiesDatabase.jsp; Kevin V. Blake et al.,
Increasing scientific standards, independence and transparency in post-authorisation studies: the role of
the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance, 21
PHARMACOEPIDEMIOLOGY & DRUG SAFETY 690 (2012).
158. Aaron Kesselheim & Jerry Avorn, The Food and Drug Administration Has the Legal Basis to Restrict
Promotion of Flawed Comparative Effectiveness Research, 31 HEALTH AFF. 2200, 2203 (2012). Infor-
mation on over 14,000 observational studies is voluntary posted on clinicaltrials.gov. See The Lancet,
Should protocols for observational research be registered?, 375 LANCET 348 (2010).
159. FDAAA, Pub.L. 110-85 (2007), § 801.
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enhance transparency of these studies, this would not speak to their quality
and in the clinical trials arena, the utility of required registration of trials
has been limited due to a lack of compliance with timely posting of trial
information and a lack of sufficient detail for syntheses such as individual
patient-level meta-analyses.160 Efforts by the Patient Centered Outcomes
Research Institute ("PCORI") and AHRQ to improve the standards for the
conduct and analysis of observational PCORI studies will be needed to
further evaluate how "nonrandomized approaches compare with or add to
randomized controlled trials in diverse fields and settings.""' Despite the-
se important efforts, it is possible that in many cases, trials will still be re-
quired because observational studies may not be able to adequately handle
selection bias.162 However, pragmatic randomized trials, which are much
less costly and more efficient than traditional randomized controlled trials,
may alleviate some of the time and cost issues associated with traditional
trials.163
In addition, it is important to (1) establish an evidentiary framework
for CER to facilitate appropriate and consistent research funding, use of
appropriate study designs (e.g. randomized controlled trials, observational
studies) for clinically meaningful CER questions, and synthesis of evi-
dence for the evaluation of the relative safety and effectiveness of drugs
and other medical interventions to discern their value; and (2) develop
methods to combine evidence from multiple sources. " Greater transpar-
ency is also needed around the evaluation of the quality of evidence of ob-
servational drug comparative effectiveness studies to inform decision-
making and establishment of standards of when these studies are rigorous
160. See generally Michael R. Law et al., Despite Law, Fewer Than One In Eight Completed Studies Of
Drugs And Biologics Are Reported On Time On ClinicalTrials.gov, 30 HEALTH AFF. 2338-2345; Hammad,
supra note 126, at 564.
161. Methodological Standards and Patient-Centeredness in Comparative Effectiveness Research: The
PCORI Perspective, 307 JAMA 1636, 1639 (2012).
162. Joe V. Selby et al., Reviewing Hypothetical Migraine Studies Using Funding Criteria From the Pa-
tient Centered Outcomes Research Institute, 31 HEALTH AFF. 2193, 2196 (2012). James S. Floyd & Bruce
M. Psaty, Observational Comparative Effectiveness Studies of Drug Therapies, 172 ARCH. INTERN. MED.
1412, 1413 (2012).
163. See Kalipso Chalkidou et al., The Role for Pragmatic Randomized Controlled Trials (pRCTs) in
Comparative Effectiveness Research, 0 CLINICAL TRIALS 1 (2012). This article points out specific exam-
ples of traditional RCTs that involve findings from studying highly selective populations which do not gen-
eralize to real world patients. pRCTs balance the internal validity of trials with the external validity of ob-
servational studies, adding another important evidence source to evaluate high value drugs (and other
interventions).
164. Tunis, supra note 148, at 1966, 70. See also, GRADE Working Group, Grading Quality of Evidence
and Strength of Recommendations, 328 BMJ 1490 (2004) (The GRADE WG framework for the evaluation
and synthesis of evidence for clinical guideline development may inform the development of such a frame-
work).
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and produce valid results.' There is a recent collaborative initiative un-
derway to enhance the transparency and evidence-based approach to eval-
uate observational CER evidence.'
In addition to CER methods and data development, as stated earlier,
approximately forty-six percent of the ARRA CER funds were allocated
for evidence development and synthesis. To evaluate the impact, it first
important to bear in mind that the total ARRA funds, $1.1 billion, are rela-
tively small in comparison to the annual cost of health care which is now
$2.8 trillion. Approximately half of the ARRA CER funding amounts to a
mere $550 million for evidence development and synthesis"', or approxi-
mately one dollar out of every $5,000 spent on health care. With respect
to funding traditional clinical CER trials, these funds will likely not direct-
ly support CER trials due to their high cost; for example, the antihyperten-
sive ALLHAT study involved more than 35,000 patients cost more than
$100 million.'68 In addition, years later, many clinicians have still not ap-
plied the main findings of the study, that older, less expensive thiazide diu-
retic drugs are as effective as newer, more expensive anti-hypertensive
drugs. Due to the limited amount of resources available, in contrast to
paying for traditional randomized controlled trials ("RCTs"), funds may be
used to support alternate evidence development (e.g., observational stud-
ies) and synthesis activities. These activities include the development of
methods for evidence synthesis, an important area in the evaluation of
drug value as clinical guideline developers and others that impact medical
practice often use systematic reviews, which synthesize comparative effec-
tiveness evidence from different evidence sources (e.g., trials, observa-
tional studies), to identify research gaps and evidence on the impact of
drugs and medical interventions on health outcomes.
Despite the importance of the ARRA funded comparative effective-
ness initiatives to enhance the evaluation of the value of drugs and other
medical interventions, there are some significant policy-related limitations
to CER studies (in addition to the aforementioned scientific limitations).
A recent article points out five important limitations: (1) economic incen-
tives may limit the utility of CER as there are winners and losers and misa-
ligned incentivizes - for example, a "loser" may be a pharmaceutical com-
165. Kesselheim & Avorn, supra note 158.
166. Nancy A. Dreyer et al., Recognizing High-Quality Observational Studies of Comparative Effective-
ness, 16 AM J. MANAGED CARE 467 (2010); Nancy A. Dreyer, Making Observational Studies Count: Shap-
ing the Future of Comparative Effectiveness Research, 22 EPIDEMIOLOGY 295 (2011).
167. Benner, supra note 142.
168. Harold Sox, The Patient-Centered Outcomes Research Institute Should Focus on High Impact Prob-
lems That Can Be Solved Quickly. 31 HEALTH AFF. 2176, 2179 (2012).
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pany that may seek to discredit evidence indicating the lack of superiority
of their drug; (2) there is often uncertainty about the results due to a lack
of evidentiary standards for different types of CER studies; (3) biases
about CER, including confirmation, pro-intervention, and pro-technology
biases; (4) the research does not address the needs of all stakeholders; and
(5) the evidence is not linked to clinical decision support which would en-
able prescribers to rapidly use the evidence for decision making.'69 These
challenges must also be addressed to maximize the impact of CER, thus
enhancing the evaluation of the value of drugs. Number (4) will be ad-
dressed by the activities of the institute created by ACA as mentioned in
the following section.
C. Patient Protection and Affordable Care Act (ACA): the Patient
Centered Outcomes Research Institute (PCORI)
As referenced above, the ACA established a public-private partner-
ship, the Patient Centered Outcomes Research Institute ("PCORI").170
PCORI is funded with $320 million in 2013 and $650 million per year for
2014 to 2019 by the United States Treasury, and a health insurance plan
assessment fee and is tasked with supporting clinical CER that will "assist
patients, clinicians, purchasers, policymakers in making informed health
decisions by advancing the quality and relevance of evidence concerning
the manner in diseases, disorders, and other health conditions can effec-
tively and appropriately be prevented, diagnosed, treated, monitored, and
managed through research evidence and synthesis."' 7' This definition is
similar to the definitions of comparative effectiveness research ("CER")
above, and emphasizes the importance of informed, evidence-based deci-
sion making by patients and clinicians. PCORI is focused on funding re-
search that informs patient and clinician decision-making, consistent with
the name of the organization.172 Pursuant to the mandate to develop a re-
search agenda based on statutory criteria, PCORI developed the institute's
research agenda, which includes the following topic areas: (1) assessment
of options for prevention, diagnosis, and treatment; (2) improving health
care systems; (3) dissemination and communication of research; (4) ad-
dressing disparities; and (5) accelerating patient-centered outcomes re-
169. Justin W. Timbie et al., Five Reasons That May Comparative Effectiveness Studies Fail to Change
Patient Care and Clinical Practice, 31 HEALTH AFF. 2168 (2012).
170. PPACA, Pub. L. 111-148, 124 Stat 727, § 6301.
171. Id. See also PCORI, How are we funded?, PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE, at
http://www.pcori.org/how-were-funded/.
172. Joe Selby et al., The Patient-Centered Outcomes Research Institute (PCORI) National Priorities for
Research and Initial Research Agenda, 307 JAMA 1583 (2012).
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search and methodology.13 Importantly, the agenda focuses on "close co-
ordination with other funders of CER, including NIH, AHRQ" and indus-
try to ensure funding of complementary not duplicative work.'74
Similar to the ARRA CER work mentioned above, the methods em-
ployed by PCORI grantees and contractors will be critical as many of the-
se studies will be either observational or randomized but not fully con-
trolled (i.e., pragmatic). Thus, many of these studies of drugs and other
medical interventions will be prone to some of the same types of con-
founding and bias and "for [such] research to be meaningful, its methodo-
logical foundation must be scientifically sound and patient centered.""'
Importantly, the draft PCORI methodology report released in June 2012
highlights the importance of studying outcomes relevant to patients (e.g.,
the impact on symptoms and function versus surrogate measures) and re-
search that is "inclusive of an individual's preferences, autonomy, and
needs, focusing on outcomes that people notice and care about such as
survival, function, symptoms, and health-related quality of life.""' This is
especially important because physicians may not understand what the pa-
tient prefers, and patient-centered outcomes are linked to improvement in
the outcomes important to patients. Research in decision aids to improve
shared decision making has born this out; for example, many patients with
benign prostate hyperplasia ("BPH") waiting for surgery were only able to
adequately communicate their preference not to have surgery after the use
of a decision aid."' A recent IOM Evidence Communication Innovation
Collaboration highlighted that although patients want to "know the risks of
each [treatment] option" and how each may impact their quality of life,
many were not provided with the option to choose amongst the treatment
options (i.e. drugs) even though they report a "better patient experience"
when they are involved in care."' Similar to the CER definition discus-
sion above, PCORI mentions that its research focuses on "how well the
different treatment choices [e.g., drugs] can work, and for whom they
173. Id. at 1584. The statutory criteria include: 1. Effect on the health of individuals and populations, 2.
Probability of improvability through research, 3. Inclusiveness of different populations, 4. Current gaps in
knowledge/variation in care, 5. Effect on health care system performance, 6. Potential to influence decision
making, 7. Patient-centeredness, 8. Rigorous research methods, and 9. Efficient use of research resources.
174. Id. at 1584.
175. Sherine Gabriel & Sharon-Lise T. Normand, Getting the Methods Right - The Foundation of Patient
Centered Outcomes Research. 367 NEW ENG. J. MED. 787, 789 (2012).
176. PCORI, Preliminary Draft Methodology Report: "Our Questions, Our Decisions: Standards for Pa-
tient-Centered Outcomes Research," 3-4 (Jun. 4, 2012), at http://www.pcori.org/assets/Preliminary-Draft-
Methodology-Report.pdf.
177. WENNBERG, supra note 136, at 226.
178. William D. Novelli et al., Recognizing an Opinion: Findings from the IOMEvidence Communication
Collaborative, 308 JAMA 1531 (2012).
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work best and are safest." in light of the significant uncertainty regarding
post-market effectiveness and safety.179 The report recommends specific
patient-centered outcomes research standards and highlights knowledge
gaps pertaining to proposals and protocols, prioritization (including input
from patients on topic generation), selection of data sources, research de-
sign, and analysis plan, research methods.'" This report and the subse-
quent updates to this report will increase confidence in this type of re-
search because robust, scientific, and transparent methods will be
developed and employed, thus increasing the potential use of the evidence
generated for patient and clinician decision making. This report also
points out the need, similar to the need mentioned above for CER, to trans-
form electronic health record data so it is researchable for patient-centered
outcomes research."' With respect to drug patient-centered outcomes re-
search ("PCOR"), the report includes a decision tree for the selection of
study design, data sources, analytic strategy, and other considerations that
will increase transparency and robustness of PCOR drug studies.' Im-
portantly, as many of the studies may be observational, the report high-
lights the research gap pertaining to methods of development for the eval-
uation of heterogeneity of treatment effect in observational studies, which
will help to increase the availability of evidence on sub-populations of real
world patients who may benefit from drugs.
Finally, as with CER, PCOR may leverage distributed research net-
works, such as the HMO Research Network, to study patient-centered out-
comes of drugs and other medical interventions in large populations.'83
Also, further research on and development of patient decision aids may
enable the use of PCOR to optimize patient decision making regarding
medical interventions, including drugs.'84 In addition, FDA's past guid-
ance on patient reported outcomes"8 and efforts to advance the develop-
ment of patient-reported outcomes as mandated under PDUJFA V will also
enhance the evaluation of outcomes important to patients in clinical trials
of drugs. "
179. PCORI, supra note 176, at 15.
180. See PCORI report, supra note 176.
181. Id.
182. PCORI, supra note 176, at 51.
183. Navanthe, supra note 145, at 1255.
184. Barry, supra note 149, at 1259.
185. FDA, Guidance for Industry - Patient-Reported Outcome Measures: Use in Medical Product Devel-
opment
to Support Labeling Claims (2009) at www.fda.gov/downloads/Drugs/Guidances/UCM 193282.pdf.
186. PDUFA Reauthorization Performance Goals and Procedures Fiscal Years 2013 Through 2017, supra
note 80, at 22.
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D. Patient Protection and Affordable Care Act (ACA): Medication
Therapy Management Legislative Initiative
The ACA included improvements to the Medication Therapy Man-
agement ("MTM") Program created under the Medicare Modernization
Act of 2003.' This includes "a[] [required] annual comprehensive medi-
cation review" for qualified patients by pharmacists to review and evaluate
medications annually.' This will enhance pharmacists' efforts to evaluate
drugs at the individual patient level and identify high value drugs, increase
adherence to these drugs which will increase their effectiveness, and iden-
tify "low value" drugs that may be duplicative or causing adverse events
that may lead to decreased patient adherence or serious drug-drug interac-
tions. In addition, this ACA section created an MTM program entitled
"Medication Management Services in Treatment of Chronic Disease," ad-
ministered through CMS.189 The law authorized grants to pharmacists and
other health care professionals to perform MTM for patients with chronic
conditions, including the identification of medication-related problems.'90
This funding in turn may further empower pharmacists by providing sup-
port for evaluating drug effectiveness and safety in individual patients with
multiple chronic conditions, enhancing patient adherence (which can in-
crease the value of drugs by increasing drug effectiveness), and identifying
and preventing drug-related adverse events.19' The health care reform-
related demonstration projects, such as patient-centered medical homes
and accountable care organizations, funded by the Center for Medicare and
Medicaid Innovation, will further facilitate pharmacists' ability to evaluate
risks associated with drugs in the real world, in addition to individual pa-
tient drug effectiveness, in patients with multiple chronic conditions on
several medications.192 However, the ARRA funds appropriated to support
187. PPACA, Pub. L. 111-148 (2010), § 10328. See also, § 274, Medication Therapy Management Em-
powerment Act of 2011, 112th Congress (In addition, Senator Hagan previously introduced a bill (which
she may introduce again) that would add to the PPACA Medication Therapy Management ("MTM") provi-
sions by expanding Part D MTM services coverage to Medicare patients with only one chronic condition,
provide for pharmacists to be adequately reimbursed for such services, and expand coverage for these ser-
vices to high risk patients, including dual eligibles and patients undergoing a transition of care).
188. Id.
189. Id. at § 3503.
190. American Pharmacists Association, Pharmacy law matters 2010: Focus on selected provisions of the
Affordable Care Act, PHARMACY TODAY, 72, 75-76 (Dec. 2010), available at
http://eleaming.pharmacist.com/Portal/Files/LeamingProducts/48fa8dbca08849689e7f9fa6a3016dea/assets/
1210 PT CE Review0/20FINAL%20113010.pdf.
191. See generally David Cutler & Wendy Everett, Thinking Outside the Pillbox - Medication Adherence
as a Priority for Health Care Reform, 363 NEW ENG. J. MED. 1553 (2010) (Lack of patient adherence is a
significant problem that can significantly decrease the utility of high value drugs. For example, eliminating
the lack of patient adherence to anti-hypertensives could prevent 89,000 deaths each year).
192. Scott Steinke, ACO Survey Shows Areas for Improvement in Drug Management, 74 (44) THE PINK
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the adoption of electronic health records ("EHRs") do not provide funds
for pharmacies which is a shortcoming because most community pharma-
cies do not currently have access to electronic health records for evaluating
drug therapies.19 3
E. Food and Drug Administration: FDA Amendments Act and
FDASIA Legislative Initiatives
FDAAA conferred FDA with additional postmarket safety authorities
to enhance postmarket drug safety and mandated the creation of a post-
market risk identification and analysis, or active surveillance, system.'94
This statutory requirement spawned the Sentinel Initiative, which has suc-
cessfully met the statutory requirements to access electronic health data
(i.e., administrative claims and electronic medical record data) for the
identification and analysis of safety issues.'95 As one key aspect of the
evaluation of the value of drugs in the postmarket setting is an evaluation
of drug safety, the Sentinel Initiative is an important FDA initiative as it
leverages the increasing availability of electronic health care data for sig-
nal detection and signal refinement."' One of the Sentinel Pilot Projects,
Mini-Sentinel, is using the same distributed network approach described
earlier to identify and evaluate drug safety issues in the postmarket setting
by enabling the active safety surveillance of drugs across disparate health
care data sources. Importantly, these active drug safety surveillance ef-
forts will complement, not replace, other evidence sources, including ob-
servational studies and clinical trials.'97 Although evaluations of unintend-
ed, serious harms that may be associated with drugs in the real world
setting do not suffer from the same extent of bias and confounding as drug
CER studies, they are still prone to bias and confounding (e.g., confound-
ing by drug indication) 9 8 because they involve secondary use of data (e.g.,
SHEET (2012); See also Marie Smith, et al., Why Pharmacists Belong in the Medical Home, 29 HEALTH
AFF. 906 (2010).
193. American Pharmacists Association, Legislative Summary: ARRA, Summary of HIT and Privacy Pro-
visions, 1 (Feb. 17, 2009).
194. FDA Amendments Act of 2007, Pub. L. 110-85, Title IX.
195. Richard Platt et al., The U.S. Food and Drug Administration's Mini-Sentinel program: status and di-
rection, 21 PHARMACOEPIDEMIOLOGY & DRUG SAFETY 1, 4 (2012).
196. Postmarket drug safety surveillance is especially important because the high prevalence of adverse
drug reactions in the real world. Over two million patients are hospitalized and 100,000 die from adverse
drug reactions each year. In addition, these reactions are the "fifth leading cause of death in the United
States." See COLLINS, supra note 8, at 233.
197. Janet Woodcock et al., Role ofPostmarketing Surveillance in Contemporary Medicine, 62 ANN. REV.
MED. 1, 9 (2011).
198. FDA, Draft Guidance for Industry: Best Practices for Conducting and Reporting Pharmacoepidemio-
logic Safety Studies Using Electronic Healthcare Data Sets (2011).
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claims are created for reimbursement purposes, not research) and are non-
randomized. Thus, the FDASIA-required report on Sentinel may help to
increase confidence in the evidence from the future Sentinel system by de-
scribing methods and circumstances in which this evidence may inform
regulatory decision making.199 The Mini-Sentinel Pilot Project already has
access to data on more than 100 million patients, as permitted by law, alt-
hough longitudinal data on most patients is more limited to one or two
years due to the high churn rate of patients in health insurance plans.200
Furthermore, the industry funded Observational Medical Outcomes Part-
nership ("OMOP"), led by the foundation of NIH, in collaboration with
FDA, is researching and developing active surveillance methods for com-
parative effectiveness and safety evaluations of drugs.201 Although Mini-
Sentinel is an important effort, the President's Council of Advisors on Sci-
ence and Technology ("PCAST") points out that Sentinel is underfunded
and recommends that Congress "provide an initial line-item appropriation
of $40 million per year to the FDA to expand post-marketing surveillance
capability, such as the Sentinel System, to cover the American population
in a rigorous, active surveillance and evaluation program to identify and
evaluate the potential benefits and risks of medical products and the popu-
lations at highest risk of adverse events."202 Thus, this request is for signif-
icantly increased funding and the use of a future system to evaluate effec-
tiveness, not just safety (currently per FDAAA, the FDA can only use
Sentinel to identify and evaluate drug safety issues).203 Furthermore, the
development of approaches to integrate active surveillance evidence with
other postmarket safety evidence sources will be challenging but will ena-
ble informed regulatory decision making.204 Meta-analytic approaches to
199. PDUFA Reauthorization Performance Goals and Procedures Fiscal Years 2013 Through 2017, supra
note 80.
200. Platt, supra note 195, at 4; Rachel E. Behrman et al., Developing the Sentinel System-A National
Resource for Evidence Development, 364 NEW ENG J. MED. 498 (2010). See also Mitchell H. Katz, Risks
and Benefits of Medications in Real-World Practice, ARCH. INTERN. MED. (2012), available at
http://archinte.jamanetwork.com/article.aspx?articleid=1379164; Sengwee Toh et al., Comparative Risk for
Angioedema Associated with the Use of Drugs that Target the Renin-Angiotensin-Aldosterone System,
ARCH. INTERN. MED. (2012), at http://archinte.jamanetwo rk.com/article.aspx?articleid=1379167 (Mini-
Sentinel investigators were commended by the Archives of Internal Medicine for recently publishing in a
high impact medical journal results from a observational cohort study of ACE-inhibitors, angiotensin recep-
tor blockers, and a novel direct rennin inhibitor alliskeren and angioedema which will inform clinical deci-
sion-making).
201. About OMOP, OBSERVATIONAL MEDICAL OUTCOMES PARTNERSHIP, available at
http://omop.fnih.org/node/293 (OMOP's research and methods development have informed FDA's Sentinel
Pilot Projects).
202. PCAST, supra note 16, at 70.
203. FDA Amendments Act of 2007. Title IX,, § 905, Postmarket Risk Identification and Analysis Sys-
tem. Public Law 110-85.
204. This need for a framework to weigh and integrate evidence also applies to CER evidence. See Robert
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statistically combine data will also be critical in light of the increasing
number of studies; under PDUFA V, FDA will be developing guidance on
meta-analysis for regulatory decision making.205 Methods for linkage to
emerging information from health information exchanges and across dif-
ferent data sources (e.g., claims, HER, HIE, personal health records) must
also be further developed.
PART III. SUMMARY AND REVIEW OF POTENTIAL FUTURE
FEDERAL LEGISLATIVE AND POLICY INITIATIVES
A. Summary
In summary, there are a number of new federal legislative and policy
initiatives that enhance the development of and evaluation of high value
drugs (HVDs). As discussed in the above sections, recent federal legisla-
tive and policy initiatives focus on: (1) incentivizing industry to invest in
drug development, including in high risk areas such as translational re-
search (2) enhancing methods to study drugs in the premarket setting (e.g.,
novel clinical trial designs and centralized IRBs), (3) increasing the use of
surrogate outcomes with required postmarket studies to evaluate health
outcome impact; (4) approaches to accelerate drug approval, including en-
hanced communication and collaboration between industry and FDA; (5)
research infrastructure development; and other approaches. In the post-
market evaluative setting, important legislative and policy-related initia-
tives include: (1) development of observational CER/PCOR study analysis
methods (e.g., to control for confounding) and methodological frameworks
for selecting appropriate study designs; (2) developing practical random-
ized controlled trial designs; (3) the development of a research infrastruc-
ture that enables faster and cost-effective evaluations, such as the com-
parative effectiveness distributed research networks, Sentinel (including
increased funds206), and HHS/ASPE multi-payer claims database; (4) in-
creased funds for the CER/PCOR research-related initiatives in light of
low funding relative to total health care costs (this ratio has historically
been low but must be increased); (5) the development of methods to take
into account patient preferences to develop patient-centered health out-
comes that will enable meaningful evaluations of drugs; and other efforts.
Epstein, The Hypothetical Migraine Drug Comparative Effectiveness Study: A Payer's Recommendations
for Obtaining More Useful Results, 31 HEALTH AFF. 2225, 2229 (2012).
205. PDUFA Reauthorization Performance Goals and Procedures Fiscal Years 2013 Through 2017, supra
note 80, at 21.
206. PCAST, supra note 16.
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Although these initiatives will be important, in light of the impending debt
crisis, it is important to evaluate potential future legislative and policy ini-
tiatives to complement current solutions, especially in light of the inability
of these initiatives to fully address the scope of the policy problem and the
relatively few dollars spent on these initiatives. As previously mentioned,
although outside the scope of this paper, efforts to translate and dissemi-
nate CER/PCOR, such as academic detailing,207 and approaches to inte-
grate evidence into prescriber workflow, such as via clinical decision sup-
port systems, will be critical to make sure that the appropriate high value
drugs are used in the right patient at the right time.
B. Potential Future Legislative and Policy Initiatives for the
Development of High Value Drugs
1. Improvement in the Clinical Trials Enterprise and Clinical Trial
Inefficiencies
The PCAST report and Francis Collins, NIH Director, have proposed
the development of clinical trial networks, which may leverage electronic
health data systems, via a collaboration between industry, FDA, and the
medical community.208 Further, these networks would ideally undergo
more efficient institutional review board ("IRB") review209 (as previously
mentioned, multi-site studies require multiple IRB approval which may be
time and cost prohibitive). This harkens back to Senator Lieberman's pro-
posal to support centralized IRB approval which would streamline clinical
trials while still protecting trial participants. This type of collaborative
work could be supported by the relatively new Reagan-Udall Foundation210
created by Congress and other organizations such as the NIH Foundation
and perhaps appropriated funds and matching funds could be used, similar
to NIH CAN's approach to funding translational research. In addition to
this PCAST proposal, FDA could consider leveraging large amounts of da-
207. See Michael Fisher & Jerry Avom, Academic Detailing Can Play a Key Role in Assessing and Im-
plementing Comparative Effectiveness Research Findings, 31 HEALTH AFF. 2206 (2012); See also, Mike
Mitka, New Physician Education Initiatives Seek to Remove the Devil from the Detailing, 306 JAMA 1187
(2011) (AHRQ let a $11.7 million contract (from the ARRA funds) to enhance unbiased, evidence-based
detailing of CER evidence to clinicians).
208. PCAST, supra note 16, at 54. Asher Mullard & Mark McClellan, An Audience with Mark McClellan,
11 NATURE REVS. DRUG DISCOVERY 668 (2012). Efforts to enhance clinical trials, including leveraging
EHRs as adoption increases, are also consistent with FDA's innovations in regulatory science to accelerate
the development of innovative drugs. See Elliott M. Antman & Robert A. Harrington, Transforming Clini-
cal Trials in Cardiovascular Disease: Mission Critical for Health and Economic Well-being, 308 JAMA
1743, 1744(2012).
209. PCAST, supra note 16, at 54.
210. REAGAN-UDALL FOUNDATION, at http://www.reaganudall.org/.
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ta from clinical trials and observational studies, knowledge of human
physiological systems, and high computing power and computer modeling
during the drug approval process. 2 11 For example, the validated Archime-
des simulation modeling approach,2 12 based on mathematical equations
representing biological systems, can model efficacy and safety in clinical
trials and drug safety and effectiveness in the real world population before
drug approval. One possible approach could involve a pilot initiative to
identify and competitively select the top companies with validated simula-
tion systems biology-based modeling capabilities (e.g., via a request for
information) and run them simultaneously with the normal new drug ap-
plication ("NDA") clinical trial approval process (and postapproval). This
would enable FDA to evaluate the consistency of these models and poten-
tial added value (including addressing aspects of uncertainty trials cannot,
such as evaluating real world patient outcomes) of these models in real-
time with actual drugs that are approved. FDA would learn if these simu-
lation modeling approaches may improve clinical trial efficiency and the
evaluation of drugs by adding more evidence that may complement, but
likely not replace, clinical trials at the premarket and postmarket stages
and potentially enhance postmarket surveillance by identifying potential
safety issues prior to drug approval.
In addition, efforts by NIH and FDA, via the Clinical Trials Trans-
formation Initiative, a public-private partnership, must continue to receive
adequate funding to continue efforts to improve clinical trials, which will
enhance the development of HVDs. 213 New approaches to combine clini-
cal trial data on drug efficacy, such as Bayesian statistical approaches, may
also enhance the rapid development of HVDs and should continue to be
improved upon.214
211. Institute of Medicine Report, supra note 6, at 10-19. Also, another initiative by NIH involves the re-
purposing of failed drugs that have already undergone clinical trial testing. This initiative has the potential
to leverage existing clinical trial data on drugs that may be used for a different purpose. See Derrick Gin-
gery, NIH Drug Repurposing Program Produces Surprise Overlaps, 74 THE PINK SHEET (Nov. 5, 2012).
212. What is the Archimedes Model?, ARCHIMEDES INCORPORATED, at
http://archimedesmodel.com/archimedes-model. In fact, Archimedes has developed a global outcome
("GO") score to evaluate the impact of medical interventions on the reduction in the risk of bad clinical
outcomes, not simply discrete surrogate measures. See generally David M. Eddy et al., The Global Out-
comes Score: A Quality Measure, Based on Health Outcomes, That Target Companies Current Care To A
Target Level Of Care, 31 HEALTH AFF. 2441 (2012).
213. Institute of Medicine Report, supra note 6, at 10-19; CLINICAL TRIALS TRANSFORMATION INITIATIVE,
at https://www.ctti-clinicaltrials.org/about-us-main.
214. Institute of Medicine Report, supra note 6, at 10-19.
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2. Development of Adaptive Drug Approval and Coverage with
Evidence Development Approaches
To enhance drug development, approval, and reimbursement, PCAST
recommends the development of adaptive approval approaches which
would involve "a series of approval stages that would iteratively expand
the market for a drug based on the evidence generated about the drug's
risks and benefits."215 Adaptive licensing requires "iterative phases of in-
formation" that are collected over time to evaluate medical product bene-
fits and risks in the real world over time.216 Coverage with evidence de-
velopment ("CED") for HVDs links reimbursement with future studies to
further evaluate drugs in the real world setting via patient registries or
studies.217 FDA precursors to this include accelerated approval, as men-
tioned, and Risk Evaluation and Mitigation Strategies ("REMS"), designed
to manage serious risks associated with drugs while still making them
available to patients with unmet medical needs.2 18 Under adaptive licens-
ing, initially the high value drug would be restricted to a small population
but then could be expanded to more patients in light of emerging evidence
of effectiveness and safety based on pre-planned studies to continue study-
ing the drug in the postmarket setting.219 Vemurafenib, a high value drug,
was approved for metastatic melanoma based on a Phase II study, but as
the adaptive licensing approach was not applied, continued studies on drug
effectiveness and safety, including in subgroups who might respond better
or worse, did not need to adhere to a pre-set timetable as to when addition-
al data would be collected and reviewed.220 However, because most drugs
are covered under Medicare Part D, CMS does not generally have the abil-
ity to use coverage with evidence development under this program.221
Thus, legislation that provides CMS with this CED authority more broadly
could enhance the evaluation of HVDs (and rewarding value) by requiring
CED programs for certain drugs that are approved quickly but whose value
215. Id.
216. Center for Medical Technology Policy, Coverage with Evidence Development and Adaptive Licens-
ing: Two Sides of the Same Coin?, 1, 3 (Feb. 2012), available at http://cbi.mit.edulwp-
content/uploads/2011/03/Coverage-with-Evidence-Development-Adaptive-Licensing Workshop-
Summary_February-2012.pdf
217. Id. at 2.
218. Id. at 3. FDA REMS with Elements to Assure Safe Use (ETASU) to manage risk enable drugs to be
approved that would otherwise not be approved due to serious safety risks (to ensure the benefits outweigh
the risks). See FDA, Guidance for Industry: Format and Content of Proposed Risk Evaluation and Mitiga-
tion Strategies (REMS), REMS Assessments, and Proposed REMS Modifications, 1, 2-3 (2009).
219. Id.
220. Id. at 6.
221. Id.
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may be more uncertain due to less rigorous approval studies.222
3. Securitization of Biomedical Research and Development (R&D)
A recent article proposed a policy solution to the dearth of R&D
funding: the securitization of biomedical R&D in an effort to add another
$30 billion in available funds for biomedical research and drug develop-
ment. 223 These funds could replace some of the significant losses in avail-
able R&D funds from pharmaceutical companies due to blockbuster drugs
coming off patent in recent years. Investors could reduce their risk by in-
vesting in a number of diverse research projects and could reap benefits
from long-term returns, which is not the case with less risky, shorter-term
investments.224 One idea of how to apply this approach would be to pay
professors for their research in exchange for royalties on any successes
from their laboratories. 25 Although the securitization approach may stim-
ulate more drug development and translational research, it may be limited
if the underlying, inefficient clinical trials paradigm remains unchanged.226
This may be comparable to the "E-room" phenomenon of throwing more
money at a problem without understanding what produces a return on in-
vestment, although it is possible that due to a lack of prior commitments
and baggage on the part of these investors, this model may be successful
as they may be more likely to fund high-risk, high-impact projects.
222. Institute of Medicine Report, supra note 6, at 8-1 1. The IOM notes that one key strategy to rewarding
value is the use of CED. Researchers have also pointed out that U.S. efforts to increase CER have not
linked this to decision making, which may limit its value and conditional coverage policies are a better ap-
proach to reward innovation and inform evidence-based decision making. Specific considerations for con-
dition approval may include: "Does current evidence suggest that the innovation is better than current prac-
tice?" "Is the collection of more information worthwhile?" and "Should we wait for more information?"
See Kalipso Chalkidou et al., Evidence-Based Decision-Making: When Should We Wait for More Infor-
mation? 27 HEALTH AFF. 1642, 1644-1646, 1651 (2008). See also, CMS Draft Guidance for the Public,
Industry, and CMS Staff Coverage with Evidence Development (Nov. 29, 2012) (In the context of coverage
decisions, CMS recently published a revised draft guidance on CED that does not provide specific eviden-
tiary thresholds for CED but does include factors CMS will consider when requiring CED. Evidentiary
thresholds for requiring CED will vary depending on the particular product (e.g., drug, device) or service
(e.g., imaging) of interest).
223. Asher Mullard, Economists propose a US $30 billion boost to biomedical R&D, 11 NATURE REVS.
DRUG DISCOVERY 735, 735-6 (2012).
224. Id. at 736.
225. Id.
226. Id. at 737.
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C. Potential Future Legislative and Policy Initiatives for the
Evaluation of High Value Drugs
1. Consideration of Drug Cost-Effectiveness, Value, and Rationing
Of Care
Despite the inclusion of costs in most definitions of high value (e.g.,
the aforementioned CBO CER definition), the recent legislative and policy
initiatives by the United States government have not focused on cost-
effectiveness. In the United Kingdom and many other countries, there are
two entities involved in the approval of drugs (1) the regulator, the Medi-
cines Health and Regulatory Agency, equivalent to the FDA in the United
States, which reviews, approves, monitors drugs, and (2) an entity that
values clinical and cost-effectiveness (value) of drugs and other medical
interventions, which in the United Kingdom is the National Institutes for
Health and Excellence ("NICE").227 The United States does not have an
equivalent NICE-type agency that evaluates comparative clinical and cost-
effectiveness for CMS. 228 As a result, drugs may be approved that are not
more clinically effective and safe relative to other drugs for the same con-
dition (e.g., relative clinical value may not be greater) or may not be cost-
effective (FDA does not consider costs, although payers do; thus, this is
not a regulatory consideration before approval). With respect to clinical
comparative and cost-effectiveness under the new PCORI, PCORI is pro-
hibited from using the results of PCOR under the ACA to "mandate cover-
age, reimbursement, or other policies for any public or private payer." 29
However, the ACA does not "bar CMS or any other public or private pay-
er from using CER research to inform its own coverage decisions." 230 Al-
so, it does not specifically mention cost-effectiveness, which means this
type of research is not prohibited. Although PCORI can fund cost-
effectiveness research, it is focusing on clinical comparative effectiveness
research and, unlike NICE, cannot make reimbursement recommendations
based on cost per disability adjusted life year or other cost-effectiveness
227. Tim Kendall et al., If NICE was in the USA, 374 LANCET 272, 272-73 (2009). NICE evaluates cost-
effectiveness based on costs of a drug per quality adjusted life years ("QALY"), which is a "measure of the
patient's preferences for his/her health state or for the outcome of an intervention." BRIAN STROM,
PHARMACOEPIDEMIOLOGY 682 (2012).
228. In addition, most comparative effectiveness studies do not also include formal cost-effectiveness stud-
ies, although information about both is necessary to full evaluate value. Michael Hochman & Danny
McCormick, Characteristics of Published Comparative Effectiveness Studies of Medications, 303 JAMA
956, 956 (2010).
229. MCDONOUGH, supra note 44 at 222-3; Peter J. Neumann, What We Talk About When We Talk About
Health Costs, 366 NEw ENG. J. MED. 585, 585 (2012).
230. Id.
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metrics. NICE has increased the uptake of new high value drugs and pa-
tients now have a right to obtain NICE recommended drugs. 231 Recently,
NICE proposed to use value-based pricing, which would consider "im-
portant factors that patients and society value," thus increasing the focus
on HVDs and other valuable treatments which may provide benefits im-
portant to patients.232 NICE also has the ability to assess emerging post-
market evidence of a drug's value to inform the adjustment of drug pricing
under the Pharmaceutical Price Regulation Scheme, thus directly linking
price and the evaluation of value.233
In the United States, although there is not an equivalent NICE, indi-
vidual payers, such as private health insurance companies and self-insured
companies, are increasingly employing value based insurance designs (de-
signs which reduce cost sharing for drugs that provide high value) for the
coverage of drugs.234 Although these companies often employ cost sharing
and tiered formularies to reduce drug costs, this may reduce adherence to
high value drugs such as generic statins, which are low cost but prevent
costly and debilitating cardiovascular events. 235  The creation via legisla-
tion of a NICE-type entity to evaluate the value of drugs (clinical com-
parative and cost-effectiveness) for coverage by CMS, the largest payer in
the United States, would likely not be politically feasible currently due to
resistance to government rationing of care, despite the fact that private in-
surance companies regularly ration and limit medical care, including
drugs, via coverage decisions and tiered formularies, and drugs that are in
short supply in the United States are rationed as needed. 236  However, as
231. Ruth Faden & Kalipso Chalkidou, Determining the Value of Drugs - The Evolving British Experi-
ence, 364 NEw ENG J. MED 1289, 1290 (2011).
232. Id. at 1291.
233. Adrian Towse, Value based pricing, research and development, and patient access schemes. Will the
United Kingdom get it right or wrong?, 70 BRITISH J. CLINICAL PHARMACOLOGY 360, 363 (2010). Of
note, unlike the U.K. and Europe, the U.S. does not employ price controls, which is one reason why drug
prices are so much higher in the U.S. HHS is prohibited from negotiating drug prices under Medicare Part
D. See Medicare Modernization Act of 2003, PUB. L. 108-173, § 1860(D)(i), Noninterference clause.
ROSEMARY GIBSON & JANARDAN PRASAD SINGH, THE BATTLE OVER HEALTH CARE: WHAT OBAMA'S
REFORMS MEAN FOR AMERICA'S FUTURE 187 (2012) (Many policy experts support enabling Medicare to
negotiate drug prices. Some experts propose providing publically determined subsidies in addition to price
negotiation to transparently support drug company R&D in light of their decreased revenue that would re-
sult from lower negotiated prices).
234. James C. Robinson, Applying Value-Based Insurance Design to High-Cost Health Services, 29
HEALTH AFF. 2009 (2010).
235. Niteesh K. Choudry et al., Assessing the Evidence for Value-Based Insurance Design, 29 HEALTH
AFF. 1988 (2010).
236. Philip M. Rosoff et al., Coping with Critical Drug Shortages: An Ethical Approach for Allocating
Scarce Resources in Hospitals, 172 ARCH. INTERN. MED. 1494 (2012). In fact, the ACA "explicitly rejects
Britain's National Health Service Model, with its global budgeting and public acceptance of prioritization
and consideration of costs." Faden supra note 231, at 1291.
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the number of Medicare patients is projected to grow from forty-six mil-
lion in 2010 to seventy-nine million in 2030, and the ratio of workers to
retirees will decline, Medicare costs will increase by more than ninety per-
cent.237 Further, the CBO stated that "projected increases in [Medicare]
spending .. . would require tax increases of an unprecedented magnitude
... under current policy, future generations will be worse off by higher
taxation or lower benefits."238
Thus, similar to Massachusetts, which passed health reform under
then-Governor Mitt Romney that insured virtually all state citizens and re-
cently approved a law to lower health care costs, Congress will have to
consider options to follow the ACA by significantly reducing health care
costs, which may likely involve a form of rationing of health care services,
including drugs.239 In a recent article, Daniel Callahan defined rationing as
"an organized effort by public or private institutions (e.g., Medicare or a
private insurer) to equitably limit the availability of some desired or need-
ed medical treatments in the name of preserving the institution as a whole
or equitably distributing a scarce resource."240 Callahan emphasizes that
rationing should be transparent and a societal policy versus being made on
an individual case-by-case basis.241  As mentioned, in the United States,
despite the rhetoric about government rationing and death panels, private
insurance companies regularly ration health care, including drugs, via
managed care approaches such as tiered formularies.242 If rationing is not
done publically, it will be done "indirectly by pushing up copayment and
deductibles to a painful, threatening level," which is much less equitable
and transparent.243 NICE uses quality adjusted life years ("QALYs") and a
cost-effectiveness threshold to ration medical treatments, including drugs,
that cost above a certain dollar amount for a given amount of quality years
of life conferred.2" Similar to the environmental regulations arena, alt-
237. Daniel Callahan, Must We Ration Health Care for the Elderly?, J.L. MED. & ETHICS 10, 11 (2012).
238. Id. at 11, quoting G.K. Kollman & D. Noschler, the Financial Outlook for Social Security and Medi-
care, CRS Report for Congress, Congressional Research Service, Washington, DC, 2004, at CRS 1-6.
239. See, John Ayanian & Philip Van der Wees, Tackling Health Care Costs in Massachusetts, 367 NEW
ENG J. MED. 790, 790-3 (2012).
240. Callahan, supra note 237, at 12.
241. Id.
242. David 0. Meltzer & Allan S. Detsky, The Real Meaning ofRationing, 304 JAMA 2292, 2293 (2012).
243. Callahan, supra note 237, at 15.
244. Although QALYs assign a value to the number of additional quality life years a medical intervention
may confer, there are several problems with assigning value to a human life. These problems been dis-
cussed in the environmental regulatory field, which often uses QALYs to evaluate environmental regula-
tions focused on rare, serious environmental health risks. See generally FRANK ACKERMAN & LISA
HEINZERLING, PRICELESS: ON KNOWING THE PRICE OF EVERYTHING AND THE VALUE OF NOTHING (2004).
See also Peter Neumann, What's Next for QALYs? 305 JAMA 1806, 1806 (2011) (Also, QALYs "may not
capture well how some individual value certain aspects of health.").
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hough QALYs enable the encapsulation of value into a single number,
they are subject to a number of controversial challenges, including: deter-
mining the appropriate value of a statistical life, how to incorporate life-
years and quality adjusted life years approaches in an equitable manner
(e.g., appropriate consideration of the elderly, who do not possess as many
potential quality years of life), and how to appropriately quantify wealth-
health considerations.2 45  Legislation could be passed that would create a
federal agency2 46 to conduct cost-effectiveness research to determine the
value of medical interventions (including drugs). Preferably, such agency
would be more politically insulated, comparable to the Federal Reserve
Board, that is not subject to the vagaries of the congressional appropria-
tions process2 47 (Another option would be to mandate PCORI to conduct
cost-effectiveness research, in addition to patient-centered outcomes re-
search). Importantly, similar to NICE,2 48 this entity could obtain input
from the public on the process of evaluating cost-effectiveness. States
such as Oregon have passed laws in the past to provide for public, open ra-
tioning of care for poor patients (e.g., Medicaid) to ensure they had access
to a basic package of health care services by surveying the public to ascer-
tain the value of critical medical care services and then evaluating the list
of services to determine their value by using a "net benefit value formula,"
including data on expected health outcomes.249 Presently it is unlikely to
be politically feasible to pursue the creation of a national cost-
effectiveness center; however, one novel approach may be for payers and
pharmacy benefit managers ("PBMs") to integrate comparative effective-
ness/patient-centered outcomes research evidence into the development of
245. See generally Jedediah Purdy, Climate Change and the Limits of the Possible, 18 DUKE ENVTL. L. &
POL'Y F. 301 (2008). For a full discussion of the limitations of cost-benefit analyses, See generally
RICHARD L. REVESZ & MICHAEL A. LIVERMORE, RETAKING RATIONALITY: How COST-BENEFIT ANALYSIS
CAN BETTER PROTECT THE ENVIRONMENT AND OUR HEALTH (2008); U.S. EXPERT PANEL, COST-
EFFECTIVENESS IN HEALTH AND MEDICINE (Marthe R. Gold et al. eds., 1996) (Despite these limitations,
the panel recommended the use of QALYs to facilitate consideration of morbidity and mortality impact in
one measure).
246. Callahan, supra note 237 at 13.
247. Uwe E. Reinhardt, An Information Infrastructure for the Pharmaceutical Market, 23 HEALTH AFF.
107, 109 (2004). See also Ruth Lopert & Marilyn Moon, Toward A Rational, Value-Based Drug Benefit
For Medicare, 26 HEALTH AFF. 1666, 1669 (2007) ("Understanding the extent to which a drug represents
value for money requires a consideration of both comparative effectiveness and comparative cost-
effectiveness."); Victor R. Fuchs, How and Why U.S. Healthcare Difers from Other OECD Countries, 309
JAMA 33 (2012) (Creating a politically insulated institution is all the more important in light of the wide-
spread distrust of government in the United States, in contrast to European countries such as the U.IC and
Germany which have robust cost-effectiveness agencies).
248. Faden, supra note 231, at 1290 (NICE is "viewed as a global leader in incorporating social values and
public engagement into the development of health policy recommendations.").
249. See Daniel M. Fox & Howard M. Leichter, Rationing Care in Oregon: The New Accountability, 10
HEALTH AFF. 7 (1991).
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formularies and value-based purchasing insurance designs.2"o This would
enable prescription drug plans and PBMs to charge lower costs for higher
value drugs and higher costs for lower value drugs (based on comparative
effectiveness research evidence meeting agreed upon standards). Incentiv-
izing patients to take medications that significantly improve their health
can save the health care system money by reducing adverse outcomes and
hospitalizations.25' In addition, the ACA created the Independent Payment
Advisory Board ("IPAB"), vilified by Republicans during the presidential
race, which will in the upcoming years recommend approaches to limit
Medicare costs if they exceed projected annual target rates; however, un-
like NICE, the IPAB is not an evaluative organization, but rather proposes
ways to reduce costs (it does not evaluate drug and medical intervention
clinical and cost-effectiveness) that are binding if Congress fails to suffi-
ciently lower costs when Medicare costs increase at a rate above a speci-
fied threshold relative to general inflation. However, its existence may be
short-lived due to opposition from Congress and health care stakehold-
ers.252
With respect to Medicare, the rising program costs are unsustainable
and it is possible that some limitations on state-of-the-art technologies may
be required, especially in the final months to years of life, which are the
most expensive.253 Although access to information on the value of drugs is
the sine qua non (essential component) of an efficiently functioning mar-
ket, prescribers and patients often lack comparative evidence of drugs'
clinical value for some important reasons as mentioned in prior sections of
this paper.254 Without this evidence of comparative clinical value, it is not
250. Michael E. Chernew et al., Comparative Effectiveness Research and Formulary Placement: The Case
ofDiabetes, 19 J. MANAGED CARE 1, 2 (2013).
251. Id.
252. PPACA, § 3403, IPAB. Health Affairs, Health Policy Brief, 4 (Dec. 15, 2011), at
http://healthaffairs.org/healthpolicybriefs/brief pdfs/healthpolicybrief_59.pdf (Starting in 2013, a new enti-
ty will have authority to curb Medicare spending if growth exceeds targets). See Henry J. Aaron, The Inde-
pendent Payment Advisory Board - Congress's Good Deed, 364 NEW ENG J. MED. 2377, 2379 (2011) (Re-
publicans have introduced bills to eliminate this Board and former presidential candidate Romney
purportedly would have repealed the entire health reform law, including the IPAB. Despite these limita-
tions, the IPAB could play an important role if it survives as it can "mobilize the power of the country's
largest health care buyer" to promote change). GIBSON & SINGH, supra note 233, at 187. (The pharmaceu-
tical industry has also fought against the IPAB because its actions might result in lower drug prices; Eli
Lilly wrote "We think that the IPAB provision should be repealed. Should we have unelected, unaccounta-
ble bureaucrats making health care decisions rather than you and your physician?"). Emily Ethridge, New
House Rules Would Amend Requirements on Medicare Board, CQ NEWS (Dec. 31, 2012), at
http://www.rollcall.com/news/newhouse ruleswould amend requirements onmedicare board-220428-
1.html (Republicans plan to limit the IPAB via House rules for the 113th Congress).
253. Cynthia E. Boyd, Medicare: It's Time to Talk About Changing It, 19 ANNALS HEALTH L. 79, 80
(2010).
254. Reinhardt supra note 247, at 111.
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possible for a new semi-public entity to evaluate the cost-effectiveness of
drugs, a key aspect of value. Although this paper does not focus on the
communication of comparative effectiveness evidence, efforts to increase
access to such evidence generated by PCORI and AHRQ, such as academ-
ic detailing,255 and to improve communication of evidence about drug
harms and benefits more generally,2 56 may increase the use of HVDs.
2. Evaluation of Comparative Efficacy and Tolerability at the
Time of Drug Approval
Physician Alec O'Connor proposes consideration of comparative ef-
ficacy and safety at the time of approval. Specifically, he points out that
under the Code of Federal Regulations, a new drug is approved on the ba-
sis of substantial evidence, namely adequate and well-controlled investiga-
tions (with the exceptions discussed above created under the FDA Mod-
ernization Act of 1997).257 Dr. O'Connor points out that this means the
law does not require a new drug to provide greater efficacy over placebo
than another approved drug for the same condition, which could result in
patients taking a newly approved drug that is less efficacious, potentially
leading to worse health outcomes.258 Randall Stafford proposed changing
the CFR to require sponsors to submit CER data to FDA. 25 9 This could be
very problematic if poor quality observational study evidence is submitted
before an evidentiary framework for this type of research is firmly estab-
lished, as this could potentially mislead prescribers about a drug's actual
value. Instead, O'Connor focuses on clinical trials and proposes "strict
FDA oversight of required active-comparator trials," which would ensure
that the trials were adequately designed to evaluate the premarket compar-
ative efficacy of treatments. 260 This would require a change to the FDA
regulations and may be infeasible as drug companies would likely be op-
posed to this approach. Opponents of this proposal have posited that (1)
FDA already exercises authority to require comparative trials if patients
may be at risk and (2) the size of the required trials would be too large;
and (3) when drugs are very expensive relative to their marginal additive
255. Fisher & Avorn, supra note 207, at 194.
256. Lisa M. Schwartz & Steven Woloshin, Using a Drugs Fact Box to Communicate Drug Benefits and
Harms, 150 ANNALS INTERN. MED 8 (2009).
257. Alec O'Connor, Building Comparative Efficacy and Tolerability into the FDA Approval Process, 303
JAMA 979, 979-80 (2010). 21 CFR 201.1(e)(6). A 2010 evaluation of CER studies also pointed out the
need for active comparator trials when feasible. Hochman & McCormick, supra note 228, at 958.
258. Id.
259. Randall S. Stafford et al., New, But Not Improved? Incorporating Comparative Effectiveness Infor-
mation into FDA Labeling, 361 NEw ENG J.MED. 1230 (2009).
260. O'Connor, supra note 257, at 980.
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benefit, payers will address this via formulary restrictions and other ap-
proaches.26 ' Although these points may be true in some circumstances,
several me-too drugs that provide marginal, comparative benefit and toler-
ability to previously approved drugs in the same class, have been approved
in recent years and many patients have been shifted to these much more
costly patented drugs, possibly in part due to significant direct-to-
consumer ("DTC") advertising, when cheaper generic drugs that provide
the same relative clinical value have been available (e.g., esomeprazole
[Nexium, the purple pill] and omeprazole [Prilosec]).262 Recently, the
pharmaceutical industry requested FDA to allow drug companies to com-
municate the results of the CER studies, many of which are observational
in nature, under the "competent and reliable" legal evidentiary standard for
product communications. 6 3 Also, FDA could change its interpretation of
the "substantial clinical experience" standard (for communication of com-
parative claims) in the future to enable communication of CER results
from PCORI and other entities.2" However, until the evidentiary stand-
ards for observational CER studies are well established, it is unlikely that
FDA will allow drug sponsor communications about these studies due to
the high potential for bias and confounding in these nonrandomized stud-
ies.265
3. Convergence of Guidelines and Guidance Documents For The
Evaluation Of Postmarket Safety and CER/PCOR Research
As mentioned above, guidelines and guidance documents have been
created by several domestic and international government (e.g., FDA,
A-HRQ, EMA, ENCePP) and independent organizations and public-private
partnerships (e.g., PCORI, ISPE, GRACE, ENCePP) for postmarket safety
and CER/PCOR research. It is important for government, independent or-
261. Scott Gottlieb, The FDA Should Not Mandate Comparative-Effectiveness Trials, AM. ENTERPRISE
INST. HEALTH POL'Y OUTLOOK 1, 3 (2011).
262. Stephane Regnier, What is the value of 'me-too' drugs?, HEALTH CARE MGMT. SC. 2013 (published
online ahead of print, Feb. 26, 2013) (In the short term, me-too drugs may provide some cost savings but in
the long term savings may be small, non-existent or negative). See also Joshua J. Gagne & Niteesh K.
Choudhry, How Many "Me-Too" Drugs Is Too Many?, 305 JAMA 711, 711 (2011).
263. See Eleanor Perfetto, John E. Bailey, Kathleen R. Gans-Brangs, et al., Communication About Results
of Comparative Effectiveness Studies: A Pharmaceutical Industry View, 31 HEALTH AFF. 2213, 2214, 2216
(2012) (Dr. Perfetto points out that payers currently use CER study evidence for coverage decisions such as
formulary coverage that do not meet FDA's "substantial evidence" standard. However, this is different
than FDA endorsing sponsors to discuss comparative effectiveness research results without widespread
agreement on standards. As standards, which may include efforts by GRACE as previously mentioned be-
come widely accepted, this FDA stance may change in the future).
264. Fox, supra note 29, at 100; 21 CFR 202.1(e)(6)(1)(2010).
265. Joseph P. Griffin et al., Regulatory Requirements of the Food and Drug Administration Would Pre-
clude Product Claims Based On Observational Research, 31 HEALTH AFF. 2188, 2189 (2012).
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ganizations, such as academics, and industry to harmonize these docu-
ments to the greatest extent feasible so they may be best used for the eval-
uation of the quality of evidence to better ascertain the value of drugs in
the postmarket setting.266
4. Leveraging Health Information Technology ("HIT") for the
Evaluation of Drugs
In Section III, this paper discussed how HHS/ASPE and FDA initia-
tives are leveraging existing healthcare data to evaluate drugs in the real
world. Government health agencies, clinicians, and HIT experts should
also leverage aggregated data to evaluate patient adherence to medications,
which will enable an evaluation of whether patients take their medications
as prescribed and whether non-adherence is due to a lack of effectiveness
or safety issues.267 As mentioned, most pharmacists, especially those in
the most accessible venue, community pharmacies, do not have access to
patients' EHRs. 268  Decisionmakers allocating future federal funding for
EHRs and the medical and pharmacy communities should consider sup-
porting new approaches that make clinical data available to pharmacies by
integrating electronic pharmacy systems so that they can evaluate the val-
ue of drugs during medication therapy management.269 In addition, if phy-
sicians have access to electronic health care data on all patients in their
practice, they may identify patients who may be exposed to serious risks of
266. Michael L. Johnson & Abhishek S. Chitnis, Comparative effectiveness research: guidelines for good
practices are just the beginning, 11 EXPERT REV. 51, 54 (2011).
267. PCAST, Report to the President: Realizing the Full Potential of Health Information Technology to
Improve Healthcare for Americans: The Path Forward, 17 (Dec. 2010); See also Lars Osterberg & Ter-
rence Blaschke, Adherence to Medication, 353 NEw ENG J. MED. 487, 487-97 (2005) (Lack of patient ad-
herence is widespread problem and a recent study found that only sixty-six percent of patients were adher-
ent to diabetes medications six months after initiation). See Aaron Mckethan et al., Seizing the Opportunity
to Improve Medication Adherence, HEALTH AFFAIRS BLOG (Aug. 28, 2012) at
http://healthaffairs.org/blog/2012/08/28/seizing-the-opportunity-to-improve-medication-adherence/. See
generally M. Christopher Roebuck et al, Medication Adherence Leads to Lower Health Care Use and Costs
Despite Increased Drug Spending, 30 HEALTH AFF. 91 (2011) (Furthermore, patients with chronic diseases
who are more adherent have higher drug costs but better health outcomes and lower overall health care
costs).
268. Diana Yap, Pharmacists can help with meaningful use, AMERICAN PHARMACISTS ASSOCIATION (Dec.
1, 2012) at http://www.pharmacist.com/pharmacists-can-help-meaningful-use (Although currently most
community pharmacists don't have access to electronic health records, Walgreens recently announced an
initiative to provide pharmacists with access to EHRs in most of its 8,000 pharmacies throughout the coun-
try. This disruptive innovation may drive the community pharmacy market to providing pharmacists with
access to EHRs and may enable community pharmacists to collaborate with hospitals to ensure seamless
transitions of care from the inpatient to outpatient setting.).
269. See PHARMACY E-HEALTH INFORMATION TECHNOLOGY COLLABORATIVE,
http://www.pharmacyhit.org/ (several pharmacist organizations have joined together under the auspices of
the pharmacy e-health initiative to advocate CMS and other decision-makers to ensure that incentives for
electronic health records and health information exchanges enable pharmacists to leverage this data for pa-
tient care).
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harm associated with drugs and take actions to mitigate this risk (e.g., high
dose simvastatin and risk of muscle damage).270 Integrating drug adverse
event reporting into EHRs, which the FDA supports, will enhance the
evaluation of postmarket drug safety.271 Further, personal health records
("PHRs"), containing clinical information, claims, and lab data, and data
directly from patients may significantly contribute to drug evaluation.272
Also, this may facilitate patients' reporting outcomes to health care profes-
sionals (and enhance patients' ability to manage their own care), and in-
form shared decision-making.2 73 Observational registries may also be in-
creasingly leveraged for the conduct of "clinical registry trials," which will
better reflect real world patient outcomes and enable trials for a larger
number of patients at a lower cost.274
5. Evaluation of Off-Label Drug Use
Off-label drug use is pervasive (about twenty percent of prescription
drug use was estimated to be off-label in 2001) and may support innova-
tion, such as information about new benefits, or increase patient harms,
such as the use of drugs that do not work and/or cause harm in the non-
indicated populations.275 Off-label drug use may be affected by a recent
decision handed down by the United States Court of Appeals for the Se-
cond Circuit, which held that a drug sales representative had First
Amendment free speech protection to discuss off-label drug use infor-
mation with physicians. 276 However, this was a "sui generis" case because
it very fact-specific, involved truthful speech, and the court stated that
FDA still has the right to regulate the marketing of drugs, including off-
label marketing, when used as part of a broader evidence base to demon-
270. American College of Cardiology Annual Scientific Session & Expo 2012: Formulary decision process
at Mayo Clinic leads to abandoning 80-mg dose of simvastatin, 47 FORMULARY 340, 340 (2012).
271. E.J. Fotsch, Electronic Health Records: The New Vehicle for Drug Labeling, Safety, and Efficacy, 91
CLINICAL PHARMACOLOGY & THERAPEUTICS 917, 918 (2012).
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strate that a sales representative is marketing the drug for off-label use (in
this case, the sole evidence was that of speech pertaining to off-label
use).277 Thus, this may not have a significant impact on off-label use. In
the United Kingdom, the National Institutes for Health and Clinical Excel-
lence ("NICE") recently published product summaries of off-label use to
summarize evidence on off-label use, although it indicated that it is not en-
couraging off-label prescribing.278 Because there is no equivalent to the
NICE agency in the United States and this may be viewed as promoting
off-label drug use, this may not be a viable option in the United States.
One approach to address off-label use would be to require drug sponsors to
discuss "possible future off-label use" when a drug is approved in ex-
change for a fast tracking of supplemental NDAs.279 Although this would
require legislation,280 it would facilitate post-marketing surveillance of ad-
verse effects in off-label populations, and it may prevent companies from
seeking "approval for a second, but easier to approve, target."28' Although
the FDA cannot regulate off-label drug use (only off-label promotion re-
lated to intended use), and thus does not have access to good evidence on
such use, CMS's coverage with evidence development and PCORI funded
research may enhance the evaluation of off-label use by studying the real
world use of drugs and determining their value.282 France recently passed
legislation that enables the creation of a temporary marketing authorization
for drugs that are used off-label on the condition that companies monitor
the drug's safety and efficacy. Although this approach may facilitate
evaluation of off-label use, it may also increase off-label use regardless of
whether or not permanent authorization is secured after the maximum
three-year test period.283
CONCLUSION
President Obama and Congress will need to take significant steps to
strengthen the economy, of which the biopharmaceutical sector is a key
277. Geoffrey R. Kaiser, What Does the Second Circuit 's Recent Decision in United States v. Caronia Not
Say?, 3 FOOD & DRUG L. POL'Y FORUM 1, 3 (2013).
278. Evidence summaries: unlicensed/off-label medicines, NATIONAL INSTITUTE FOR HEALTH AND
CLINICAL EXCELLENCE, at http://www.nice.org.uk/mpc/evidencesummariesunlicensedofflabelmedicines/
home.jsp.
279. Stafford, supra note 275, at 924.
280. Id.
281. Id.
282. Amy E. Todd, No Need for More Regulation: Payors and Their Role In Balancing The Cost and Safe-
ty Considerations of Off-Label Prescriptions, 37 AM. J.L. & MED. 422, 443 (2012).
283. Joseph Emmerich et al., France's New Framework for Regulating Off-Label Use, 367 NEW ENG. J.
MED. 1279, 1281 (2012).
555
DEPAUL JOURNAL OF HEALTH CARE LAW [VOL. 14.3:503
part, and lower costs, of which health care (including drugs) costs, are in-
creasingly the most significant part. These costs are rising more rapidly
per year than the average increase in income over the past decade.284 The
President has emphasized the importance of increasing investments in
R&D more generally because, despite the importance of this research to
American competitiveness, the percentage of federal funds spent on R&D
as a percentage of GDP has "declined by 60% in 40 years," according to a
2005 National Academies Report that was developed at the encouragement
of the House and Senate.285 Considering the unprecedented economic
crossroads in our country, the President needs rally public and congres-
sional support to effectuate the policy initiatives referenced in this paper.
In addition, the President will need to support the rapid evaluation, imple-
mentation and uptake of the ACA insurance and health care delivery-
related reforms (e.g., Accountable Care Organizations and Patient-
Centered Medical Homes), and develop new approaches to support high
value health care (including drug therapy) that can improve patient health
outcomes, decrease the approximately $750 billion per year in health care
waste, and bend the cost curve of health care (including drugs).
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